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2. Abbreviations 
	  
A adenine 
ActRI activin receptor type I 
ActRIIA activin receptor type IIA 
ActRIIB activin receptor type IIB 
ActRIIB/IGF-IR receptor ratio (ratio of ActRIIB and IGF-IR) 
Ala alanine 
ARP acidic ribosomal protein 
Asn asparagine 
ATPase adenosine triphosphatase 
BEHc/c Compact Berlin High Line mouse line 
bHLH basic helix-loop-helix 
BMP bone morphogenetic protein 
C cytosine 
cDNA complementary desoxyribonucleic acid 
Cmpt Compact 
CONT human healthy controls 
DAB diaminobenzidine 
DEP diethyl pyrocarbonate 
DCM dilated cardiomyopathy 
DNA desoxyribonucleic acid 
dNTP desoxynucleotide triphosphate 
DTT dithiotreitol 
DUHi Dummerstorf high inbred (mouse line)    
EDL extensor digitorum longus (muscle) 
FLRG follistatin-like related gene 
G guanine 
GASP1 growth and differentiation factor associated serum protein 
GAPDH glycerinaldehide-3-phosphate dehydrogenase 
Gastro gastrocnemius (muscle) 
GDF-8 growth/differentiation factor 8 (=Mstn) 
Glu glutamic acid 
Gly glycine 
HE hematoxylin-eosin  
Hprt and HPRT hypoxantine guanine phosphorybosyl transferase 
ICM ischemic cardiomyopathy 
IGF-I insulin-like growth factor I 
IGF-IR IGF-I receptor 
IGF-I signaling index multiplied value of IGF-I x IGF-IR transcript levels 
Ile isoleucine 
LAP latency-associated peptide 
Leu leucine 
LTBP3 covalent binding to latent TGF-beta binding protein 
LV left ventricle of human heart 
4	  
	  
Lys lysine 
m. musculus 
MAPK mitogen activated protein kinase 
MHC myosin heavy chain  
min minutes 
miR-208 microRNA-208 
MMLV-RT Moloney Murine Leukemia Virus Reverse Transcriptase 
MRF myogenic regulatory factor (family) 
Mstn signaling index multiplied value of Mstn x ActRIIB transcript levels 
Mstn/IGF-I growth factor ratio (ratio of Mstn and IGF-I signaling) 
Mstn/IGF-I signaling index (Mstn x ActRIIB)/(IGF-I x IGF-IR) transcript levels 
mRNA messenger RNA 
Mstn myostatin 
mtDNA mitochondrial DNA 
MyoD myogenic differentiation 1 (transcription factor) 
myf5 myogenic factor protein 5 (transcription factor) 
NYHA New York Heart Association 
PBS phosphate buffered saline  
Phe phenylalanine 
PI3K phosphoinositide 3-kinase 
PKB protein kinase B/Akt 
PTEN phosphatase and tensin homolog 
RV right ventricle of human heart 
qRT-PCR quantitative reverse transcriptase polymerase chain reaction 
Quadr quadriceps (muscle) 
RNA ribonucleic acid 
rpm revolutions per minute  
S interventricular septum of human heart 
SDH succinate dehydrogenase 
Ser serine 
Smad Caenorhabditis elegans protein SMA (=small body size) 
Mothers Against Decapentaplegic (MAD): homologous to 
Drosophila protein 
SOL soleus (muscle) 
SolD Solution D 
T thymine 
TA tibialis anterior (muscle) 
TBE Tris/boric acid/EDTA (ethylene diamine tetraacetate) 
TGF-β transforming growth factor β 
Tris tris-hydroximethyl-aminomethane 
 
 
 
 
  
5	  
	  
3. Summary 
Myostatin (Mstn) is an important negative regulator of skeletal muscle growth. 
However, it plays also a crucial role in governing cardiomyocyte growth, heart metabolism 
and contraction. Our aim was to describe different aspects of Mstn signaling in skeletal 
muscle and heart tissue. To this end, two different model systems have been used in our 
experiments: (1) the Mstn mutant Compact (Cmpt) mice and (2) healthy and pathological 
human hearts.  
The hypermuscular Cmpt mice carry a 12-bp natural mutation in the Mstn propeptide, 
with additional modifier genes being responsible for the phenotype. Muscle cellularity of the 
fast tibialis anterior (TA) and extensor digitorum longus (EDL) as well as the mixed-type 
soleus (SOL) muscles of Cmpt and BALB/c mice was examined by immunohistochemical 
staining of the myosin heavy chain (MHC) proteins. In addition, transcript levels of MHC 
isoforms were quantified by qRT-PCR.  
On the other hand, gene expression of Mstn and IGF-I, the two major but mostly 
counteracting regulators of heart tissue have been investigated in different regions (septum, 
left and right ventricles) of healthy or dilated (DCM) and ischemic cardiomyopathic (ICM) 
patient hearts. A comprehensive qRT-PCR analysis was carried out by measuring the 
expression of Mstn, its receptor Activin receptor IIB (ActRIIB), IGF-I, IGF-I receptor (IGF-I 
receptor), as well as microRNA-208, the negative post-transcriptional regulator of Mstn.  
According to our results all investigated muscles of Cmpt mice were significantly 
larger compared to wild type characterized by fiber hyperplasia of different grade. Fiber 
hypertrophy was not present in TA, however, EDL muscles showed specific IIB fiber 
hypertrophy while the (I and IIA) fibers of SOL muscles were generally hypertrophied. Both 
the fast TA and EDL muscles of Cmpt mice contained significantly more glycolytic IIB fibers 
accompanied by decreased number of IIX and IIA fibers, however, this was not the case for 
the SOL muscles. In summary, Cmpt mouse, inspite of its complex genetic background, 
shows similarities (at least in fast muscles) to Mstn knockout mice in terms of muscle 
cellularity and glycolytic muscle phenotype, suggesting that the lack of Mstn is responsible 
for these morphological changes. However, based on the more pronounced hyperplasia in 
Cmpt fast muscles as well as the different cellularity and oxidative phenotype of Cmpt SOL, 
additional studies are needed to elucidate the molecular mechanisms of Mstn inactivity and 
the possible role of modifier genes in Cmpt mice.  
In our human heart study, we have found that in healthy control hearts the ratio of 
Mstn/IGF-I signaling was significantly higher in the left ventricle/septum than in the right 
ventricle. Moreover, Mstn transcript levels were significantly upregulated in all heart regions 
of DCM but not ICM patients. However, the ratio of Mstn/IGF-I signaling remained increased 
in the left ventricle/septum compared to the right ventricle of DCM patients (similar to 
healthy hearts). In contrast, in ICM hearts significant transcript changes were detected mainly 
in IGF-I signaling. In paralell with these results microRNA-208 showed mild upregulation in 
the left ventricle of both DCM and ICM hearts. This is the first demonstration of a spatial 
asymmetry in the expression pattern of Mstn/IGF-I in healthy hearts, which is likely to play a 
role in the different growth regulation of left vs. right ventricle.  Moreover, we identified 
Mstn as a massively up-regulated gene in DCM but not in ICM as part of potential 
compensatory mechanisms in the failing heart. 
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4. Introduction  
4.1. Significance of myostatin 
Since its identification in 1997 (McPherron et al. 1997), growth differentiation factor 8 
(GDF8), also called myostatin (Mstn) has been considered as a novel and unique endogenous 
negative regulator of skeletal muscle growth and maintenance. Mstn is a member of the TGF-
β (transforming growth factor β) superfamily, mainly expressed in skeletal muscle, with less, 
but still significant expression in the heart (Sharma et al. 1999) and adipose tissues 
(McPherron and Lee 2002). Enhanced production of Mstn inhibits skeletal muscle growth and 
decreases muscle mass (e.g. in cachexia, muscle dystrophy or aging) while Mstn mutations 
cause hypermuscular phenotype in several different species. Furthermore, Mstn plays a 
crucial role in the regulation of cardiomyocyte growth as well as in the maintenance of 
oxidative metabolism and contractility of the heart (Biesemann et al. 2014). In heart failure 
patients myocardium produces and secretes Mstn protein into the circulation thereby 
inhibiting skeletal muscle growth leading to cachexia (Heineke et al. 2010). Mstn secreted by 
skeletal muscles might also have an impact on the heart and adipose tissues. How adipose 
tissues are regulated by Mstn is still debated, however Mstn deficiency inhibits adipogenesis 
and improves insulin sensitivity (McPherron and Lee 2002; Guo et al. 2009). Its mechanism 
of action has not been clarified in its full complexity so far, although it might be a promising 
therapeutical target molecule in both metabolic and muscle diseases. 
 
4.2. Molecular signaling mechanisms of myostatin 
Mstn is synthetized as a precursor protein from its respective gene and the biologically 
active form develop in further steps. First, promyostatin is produced from pre-promyostatin 
by the cleavage of the signal peptide from the N-terminal end in endoplasmic reticulum  
(Fig. 1). Promyostatin is either modified intracellularly or secreted to the extracellular matrix 
(Anderson et al. 2008). As a next step, mature Mstn and LAP (latency associated protein) 
propeptide are produced through cleavage of promyostatin by furin proteases (Lee 2004). 
Then mature Mstn forms a dimer through disulfide bridges, with the propeptides binding non-
covalently to the N-terminal end of Mstn. 
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Figure 1. Synthesis and secretion of myostatin. 
 
After secretion or elimination from extracellular matrix, the Mstn-propeptide complex 
enters circulation where Mstn dimer is activated by other proteases ((paired dibasic amino 
acid-cleaving enzyme (PACE) or matrix metalloproteases (bone morphogenetic protein 
(BMP)-1/tolloid)) (Otto and Patel 2010), by cutting off the propeptide from the complex 
(Rodgers and Garikipati 2008). Upon reaching target cells, Mstn binds to activin type IIB 
receptor (ActRIIB), which dimerizes with and phosphorylates type I receptor (ActRI) (Elkina 
et al. 2011) (Fig. 2). Mstn acts through different intracellular pathways with Smads 
representing the classical way to transduce Mstn effects (Lee 2004). After receptor activation, 
Smad2 and Smad3 become phosphorylated forming a heterodimer, which in turn enters the 
nucleus and binds to regulatory gene regions. Smad2/smad3 complex represses expression of 
myogenic transcription factors (myoD, myf5, myogenin) (Massague 1998; Kollias and 
McDermott 2008), thereby inhibiting myoblast proliferation and differentitation (Langley et 
al. 2002). Mstn expression is regulated by an endogenous negative feedback mechanism 
through inhibition of Smad2/3 complex by Smad7 (Chen et al 1996; Forbes et al. 2006). Mstn 
has also been reported to regulate the expression of myogenic factors by an alternative 
mechanism involving mitogen activated protein kinase (MAPK) pathway (Philip et al. 2005).  
Insulin-like growth factor I (IGF-I) was also shown to play a crucial role in the 
regulation of muscle mass, but in contrast to Mstn, IGF-I supports skeletal and heart muscle 
growth (Serneri et al. 1999). Numerous studies have demonstrated that Mstn and IGF-I 
counteract each other through different mechanisms. IGF-I as a positive regulator of muscle 
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mass, activates mTOR pathway through the central molecular switch Akt (protein-kinase B), 
which in turn enhances protein synthesis, while inhibits protein degradation by depressing 
FoxO activity and the transcripition of E3 ubiquitine ligases (MURF-1, atrogin-1) (Elkina et 
al. 2011). Mstn have been shown to influence IGF-I pathway through inhibition of Akt and 
underlying factors (FoxO, MuRF1, Atrogin) but also might activate PTEN (phosphatase and 
tensin homolog) which in turn inhibits PI3K/Akt pathway (Ji et al. 2008). As a consequence, 
Mstn induces protein degradation while inhibits myoblast proliferation and differentiation; on 
the contrary, IGF-I facilitates protein synthesis and cellular proliferation and differentiation in 
a dynamically regulated manner (Fig. 2) (Elkina et al. 2011).  
 
Figure 2. Interplay of myostatin and IGF-I signaling pathways in skeletal muscle. ActRIIB/I: activin 
receptor IIB/I, IGF-I: insulin-like growth factor I, IGF-IR: IGF-I receptor, IRS: insulin receptor substrate, PDK1: 
phosphoinositide-dependent kinase-1, Akt: protein kinase B, mTOR: mammalian target of rapamycin, p70: 
hypothetical protein, FoxO: forkhead box protein, sub-group O, MURF-1: muscle RING-finger protein-1, 
Atrogin-1: E3 ubiquitin ligase, p21: tumor suppressor protein, Smad 2/3: Sma-MAD (Mothers against 
Decapentaplegic) protein, myoD: myogenic differentitation protein 1. 
 
Extracellular molecules play also an important role in modulating Mstn’s effect. Follistatin, a 
positive regulator of muscle growth, binds directly to Mstn thereby inhibiting its activity (Fig. 
2) (Lee and McPherron 2001). On the other hand, growth and differentitation factor 
associated serum protein (GASP-1) can cleave Mstn propeptide (Hill et al. 2003) while 
covalent binding to latent TGF-beta binding protein 3 (LTBP3) leads to the inactivation of 
Mstn (Anderson et al. 2008). In summary, once Mstn is inhibited, independent of the 
underlying mechanism Mstn defect results in a hypermuscular phenotype. 
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4.3. Skeletal muscle development and adult muscle phenotype  
Skeletal muscle development is controlled by a complex regulatory network of several 
different factors. MyoD, myogenin, myf5 and MRF4 (myf6) all belong to the basic helix-
loop-helix (bHLH) myogenic regulator factor (MRF) family and are crucial regulators of 
myogenic determination and differentiation. Through their sequential action, mesodermal 
somitic precursor cells form myoblasts which then proliferate (resulting in muscle growth by 
increasing cell number = hyperplasia), and fuse with each other to give rise to multinucleated 
myotubes (Chargé and Rudnicki 2004). Myotubes start growing (resulting in muscle growth 
by increasing cell size = hypertrophy) as long as mature post-mitotic muscle fibers are fully 
developed characterized by expression of typical muscle specific proteins such as myosin and 
actin, creatine kinase, calcium regulatory proteins and others (Schiaffino and Reggiani 2011). 
Altogether, structural and functional proteoms define muscle fiber phenotype. According to 
the ATPase activity of myosin heavy chains (MHC), slow type MHC I and fast type MHC II 
are distinguished giving rise to type I and type II fibers, respectively. Within type II fibers, 
oxidative MHCIIA, oxidative-glycolytic MHCIIX and glycolytic MHCIIB isoforms are 
identified, representing the dominating isoforms in type IIA, IIX and IIB fibers, respectively. 
Moreover, hybrid fibers containing two or more closely related MHC isoforms (I/IIA, 
IIA/IIX, IIX/IIB) are also present in muscles (Bloemberg and Quadrilatero 2012) which 
reflect the high capacity of muscle tissue to adapt to different physiological or pathological 
requirements defined as muscle plasticity. Oxidative or glycolytic metabolic characteristics of 
muscle fibers always corresponds to MHC isoforms, i. e. to the speed of muscle contraction. 
Regulation of fiber types is only partly understood, but Mstn might be one of the candidates 
which play an important role in this process (Bloemberg and Quadrilatero 2012). 
 
4.4. Myostatin mutations in skeletal muscle 
4.4.1. Artificial myostatin mutations 
Mstn knock out (KO) mouse line has been created in order to analyze Mstn effects on 
skeletal muscle (McPherron et al. 1997). According to this very first report Mstn KO mice 
show hypermuscular phenotype caused by combined effects of muscle hyperplasia and 
hypertrophy, however, the ratio of hyperplasia to hypertrophy differed between the 
investigated muscles (Fig. 3). Moreover, a massive glycolytic shift characterized by increased 
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number of glycolytic IIB fibers has been detected in Mstn deficient mice pointing to the 
important role of Mstn in glycolytic versus oxidative fiber type determination (Carlson et al. 
1999; Girgenrath et al. 2005; Hennebry et al. 2009; Wang et al. 2012). 
 
Figure 3. The hypermuscular phenotype of myostatin knock out mice compared to control line (McPherron 
et al. 1997). 
 
4.4.2. Natural myostatin mutations 
Similar to Mstn KO mice, several different organisms such as Piedmontese and 
Belgian Blue cattles (Kambadur et al. 1997; McPherron and Lee 1997; Grobet et al. 1997), 
dog (Mosher et al. 2007), pig (Stinckens et al. 2008), Texel sheep (Johnson et al. 2005; Clop 
et al. 2006) and human (Schuelke et al. 2004) have been reported to carry naturally occuring 
mutations of Mstn (Fig. 4). Most of them result in an inactive protein caused by either an 
early STOP codon or a frameshift mutation in the bioactive domain of Mstn (McPherron and 
Lee 1997; Mosher et al. 2007; Boman et al. 2009). Intriguingly, a missplicing of the Mstn pre-
mRNA was responsible for hypermuscularity observed in a human infant (Schuelke et al. 
2004) (Fig. 4). In summary, each mutation resulted in a hypermuscular phenotype 
characterized by different ratios of hyperplasia to hypertrophy. 
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Figure 4. Natural myostatin mutant organisms. Piedmontese (A) (Rodgers and Garikipati 2008) and Belgian-
blue cattles (B) (McPherron and Lee 2007), bully whippet (C) (www.dogforum.net), Texel sheep (D) 
(www.signalinggateway.org) and a 7-month-old human infant (E) (Schuelke et al. 2004). 
 
4.4.3. The Compact mutation of the myostatin gene 
 In contrast to aforementioned mutations, another mechanism of Mstn inactivation 
induces the hypermuscular phenotype of the Compact (Cmpt) mice. The genetic background 
of the founder BEHi (Berlin High inbred) line is not well defined since it was derived from an 
out-bred line founded from mice which were bought from pet shops more than 40 years ago 
(Bünger et al. 2001). The mouse line was initially selected on protein mass (Weniger et al. 
1974), further on high body weight/low fat content (Valle Zarate et al. 1994) and finally on 
body weight (Bünger et al. 2004). The ’Cmpt’ line in Berlin was derived from the first mice 
seen in early generations of the BEH line showing this phenotype. The new Cmpt line was 
selected on a muscularity score by visual inspection (Szabó et al. 1998; Varga et al. 2003, 
2005). Animals of the Berlin Cmpt line were used as founders for the Hungarian Cmpt line, 
and there was no further exchange of genetic material between the laboratories in Berlin and 
Hungary. The Hungarian subpopulation of the Cmpt mice was inbred and kept by Géza 
Müller until 2010 in the Institute for Animal Biology, Agricultural Animal Center (Gödöllő, 
Hungary), and in EGIS Pharmaceuticals (Budapest, Hungary). Analysis of the Hungarian 
inbred subpopulation of the Cmpt line identified Mstn as the major gene containing a 12-bp 
non-frameshift deletion in the propeptide which resulted in removal of five amino acids (Leu 
[224], Gly [225], Ile [226], Glu [227], Ile [228]) while producing a new amino acid (Phe) 
instead (Fig. 5). Intriguingly, although the biologically active part of the molecule was 
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unaffected (Varga et al. 1997), a massive hypermuscular phenotype has been developed in 
Cmpt mice the mechanism of which has not been clarified so far.  Nevertheless, additional 
modifier genes seem to be essentially involved in determining the full expressivity of the 
hypermuscular Cmpt phenotype (Fig. 5); however these genes have not been identified yet 
(Szabó et al. 1998; Varga et al. 2003, 2005).	  To date, only few studies provided phenotypical 
or molecular analysis of the Cmpt mice (Bünger et al. 2004; Rehfeldt et al. 2005; Amthor et 
al. 2007, 2009), although this line represents, in contrast to Mstn KO, a complex and mainly 
unknown mechanism of Mstn-dependent hypermuscularity. 
 
Figure 5. Natural mutation in the propeptide region of myostatin causes a hypermuscular phenotype in 
Cmpt mice. Mstn: myostatin, G: guanine, A: adenine, T: thymine, C: cytosine, Glu: glutamate, Ser: serine, Asn: 
asparagine; Leu: leucine, Gly: glycine, Ile: isoleucine, Lys: lysine, Ala: alanine, Phe: phenylalanine.  
 
 
4.5. Overexpression of myostatin and its consequences in skeletal muscle 
Enhanced production of Mstn leads to decreased muscle mass not only in Mstn transgenic 
mice, but also in cachectic patients, muscle dystrophies or aging (Rodgers and Garikipati 
2008). Therefore, selective inhibition of Mstn may have outstanding clinical relevance by 
improving regeneration and growth in diverse skeletal muscle disorders and muscle wasting 
syndroms (Bogdanovich et al. 2002). Recently, clinical trials have been initiated in human 
patients that rely on inhibition of Mstn. Although several approaches have been proposed to 
inhibit Mstn signaling the full complexity of Mstn pathway has not been disclosed so far. 
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4.6. Role of myostatin in the heart under physiological and pathological conditions 
Mstn, the growth inhibitor of skeletal muscle (McPherron et al. 1997) plays a 
significant role in myocardial physiology and pathophysiology as well. Sharma and his 
colleagues were the first to demonstrate that Mstn was expressed in fetal and adult heart 
(localized to Purkinje fibers and cardiomyocytes) suggesting that Mstn has an impact on 
cardiac development and growth. They also showed that Mstn expression was upregulated in 
post-infarct heart tissue (Sharma et al. 1999). Transgenic overexpression of Akt in 
hypertrophied hearts or mechanical stress in volume-overload heart failure both induced 
dramatic upregulation of Mstn (Cook et al. 2002; Shyu et al. 2006). Intriguingly, increased 
Mstn protein levels were reported by George et al. in heart biopsies of patients suffering from 
severe congestive heart failure (CHF) (George et al. 2010). These data implied an important 
role of Mstn in heart tissue and induced a significant new direction of Mstn research. 
However, by creating and analyzing various Mstn mutants several discrepant conclusions 
have been arised in the past few years.	  Germ-line inactivation of Mstn yielded conflicting 
results, describing no effect on cardiac hypertrophy or function (Morissette et al. 2006; Cohn 
et al. 2007) or reduced ejection fraction and eccentric hypertrophy (Rodgers et al. 2009; 
Jackson et al. 2012). Similarly, lineage-specific deletion of Mstn in cardiac progenitor cells 
revealed no differences in cardiac size and function in young mice (Heineke et al. 2010) 
whereas constitutive overexpression of Mstn in the heart (Heineke et al. 2010) and, in the 
heart and skeletal muscle (Reisz-Porszasz et al. 2003; Artaza et al. 2007) reduced cardiac 
mass and cardiomyocyte proliferation without effects on cardiac systolic function.  
To date, only one study has addressed the consequences of acute Mstn inhibition in the 
adult heart as well as the role of Mstn in the regulation of metabolic changes and its impact on 
cardiac hypertrophy and heart failure. Biesemann et al (2014) have recently reported that 
conditional cardiac-specific inactivation of Mstn in the adult murine heart leads to enhanced 
glycolysis, increased glycogen storage, and cardiac hypertrophy, resulting in heart failure and 
increased lethality. Thus, Mstn has been identified as an important regulator of myocardial 
metabolism and growth, which suppresses AMP-activated kinase (AMPK) activity in 
cardiomyocytes to prevent acquisition of a fetal (glycolytic) metabolic pattern, thereby 
stabilizing the oxidative metabolic status of adult cardiomyocytes and restricting cardiac 
hypertrophy. To this end, Mstn upregulation in heart failure patients seems to be a 
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compensatory reaction to exert cardioprotective effects, however long-term activation of Mstn 
signaling in the heart might induce adverse side effects i. e. fibrosis as well (Artaza et al. 
2008; Biesemann et al. 2015). 
 
4.7. Interplay between myostatin and IGF-I in the heart 
Mstn has been identified as a key regulator of heart function but its interaction with IGF-I has 
not been clarified in its full complexity. IGF-I was shown to play a pivotal role in 
cardiovascular physiology and aging (Ungvari and Csiszar 2012, Bailey-Downs et al. 2012, 
Toth et al. 2014). In concert with insulin itself, IGF-I proved to be a positive regulator of 
cardiac growth and contractility under both physiological and pathological conditions (Serneri 
et al. 1999, 2001; Palmieri et al. 2002; Barton et al. 2005; Pucci et al. 2009; Arcopinto et al. 
2013; Madonna et al. 2014). Previous in vitro studies described a tight interplay between 
Mstn and IGF-I (Shyu et al. 2005; Morrisette et al. 2006, 2009; Yang et al. 2007). Blocking 
the IGF-I/PI3K/Akt pathway in skeletal muscle-specific C2C12 cells rendered them to 
undergo apoptosis in response to Mstn. On the other hand, Mstn expression in C2C12 cells 
was paradoxically induced by IGF-I treatment through PI3K/Akt pathway suggesting a 
possible feedback regulation between IGF-I and Mstn (Yang et al. 2007). Indeed, cyclic 
mechanical stretch enhanced Mstn expression (both mRNA and protein) in cultured rat 
neonatal cardiomyocytes which was mediated by IGF-I (Shyu et al. 2005). Gaussin and Deprè 
(2005) suggested that Mstn might be a cardiac chalone of IGF-I, since cardiac growth induced 
by IGF-I was feed-backed by the overexpression of the negative growth regulator Mstn. 
According to the hypothesis, chalones are secreted by specific tissues and provide a negative 
feedback mechanism to control the size of tissue that produces it (Bullough and Laurence 
1960; Gaussin and Deprè 2005).  
MicroRNAs (miRs) are small noncoding RNAs that negatively regulate cardiac gene 
expression under both physiological and pathological conditions with a potential impact on 
cardiac Mstn or IGF-I expression as well. Indeed, microRNA(miR)-208, encoded by the 
intronic region of the MHC gene has been reported to be a negative regulator of Mstn 
expression and to play a crucial role in pathological cardiac hypertrophy and fibrosis (Callis et 
al. 2009). In line with this, miR208 was upregulated in dilated cardiomyopathy (Satoh el al. 
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2010) as well as in myocardial infarction (Bostjancic et al. 2010) and ischemia (Varga et al. 
2014). 
No studies have systematically analyzed the relevance of the possible reciprocal 
regulation of Mstn and IGF-I at the gene expression level in healthy or failing human hearts, 
nor the potential role of miR-208 under these conditions. Previous investigations focused only 
on Mstn protein activation that has been shown to be accelerated in hearts of dilated or 
ischemic cardiomyopathic patients (DCM or ICM, respectively) (George et al. 2010). 
Moreover, no data exist in the literature about the expression pattern of Mstn in comparison 
with IGF-I and their receptors in various regions (i. e. left ventricles (LV) versus right 
ventricles (RV)) of the human heart. Given the different functional requirements LV and RV 
should cope with, and the markedly different development of these regions, one could assume 
that the gene expression pattern of Mstn and IGF-I signaling might show remarkable spatial 
differences under both physiological and pathological conditions.  
 
4.8. Systemic myostatin: crosstalk between different tissues 
Although it has been known for several years that skeletal muscle produce and secrete 
Mstn into circulation thereby supporting its systemic action besides its local effects (Fig. 6, 
Breitbart et al. 2011), no data have been available about the potential secretion of Mstn from 
the heart or adipose tissues. Recently, heart failure patients with elevated Mstn protein levels 
in cardiac tissue revealed increased Mstn serum levels as well (George et al. 2010; Gruson et 
al. 2011). Moreover, heart specific overexpression of Mstn in transgenic mice increased 
circulating serum Mstn levels by three- to fourfold, causing a significant reduction in skeletal 
muscle weight (Heineke et al. 2010). On the contrary, heart-specific deletion of Mstn in mice 
prevented skeletal muscle atrophy in heart failure after aortic banding (Heineke et al. 2010). 
These results demonstrate that Mstn secreted from the heart under pathological conditions 
might have an impact on skeletal muscle growth (Fig. 6, Breitbart et al. 2011). Although the 
role of adipose tissues in maintaining circulatory levels of Mstn is currently unclear, Mstn 
seems to be essential in coordinating skeletal muscle and heart function and metabolism. 
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Figure 6. Crosstalk between different tissues through systemic myostatin action. Skeletal muscle and the 
heart (and potentially adipose tissue) secrete myostatin into circulation. Skeletal muscle growth is regulated by 
systemic and local myostatin, sequentially activated by the cleaveage of furin convertases and BMP-1/tolloid 
proteinases. During heart failure, cardiac and serum myostatin levels are increased (Breitbart et al. 2011). 
 
 
5. Aims 
1. To describe the muscle phenotype of the Mstn mutant Cmpt mice using morphological 
assessments in order to uncover the combined effects of the unconventional 
propeptide (Cmpt) mutation in Mstn and the unknown modifier genes in the genetic 
background. 
2. To analyze transcript pattern of Mstn versus IGF-I with their respective receptors in 
different regions of healthy and pathological human hearts and to reveal their spatial 
regulation in healthy hearts or potential transcript alterations in dilatative (DCM) 
versus ischemic cardiomyopathic (ICM) patients. 
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6. Materials and Methods 
6.1. Mouse studies: Animals and experimental design 
The Mstn mutant Cmpt mice have been kept in the Institute of Biochemistry (Faculty 
of General Medicine, University of Szeged, Hungary). A suitable genetic control mouse line 
of Cmpt mice was not available at the time of our experiments given the complex and mainly 
unknown genetic background of the Cmpt mouse strain. Therefore, BALB/c mice serving as 
wild-type control were purchased from Biological Research Centre of Szeged, Hungary. 
Male, 2.5 month (10-12 week)-old male Cmpt (44-50,7 g) and BALB/c (24-28g) mice were 
used for the experiments (n=5-10). Typical hindlimb muscles (m. quadriceps (Quadr), m. 
tibialis anterior (TA), m. extensor digitorum longus (EDL) m. soleus (SOL) and m. 
gastrocnemius (Gastro)) of Cmpt and BALB/c strains were removed under intraperitoneal 
anaesthesia (3% chloral hydrate, 0.15ml/10g body weight). For comparison of body and 
muscle weights as well as for TA muscle fiber analysis, 4, 7, 12, 18, and 23-month-old Cmpt 
male mice were also used. All muscles were weighed and frozen in isopenthane/liquid 
nitrogen and kept at -80°C until further use. TA, EDL and SOL muscles of BALB/c and 
hypermuscular Cmpt mice from the right leg were used for morphological and 
immunohistochemical analysis while RNA isolation followed by quantitative RT-PCR was 
carried out from the contralateral TA counterparts.  
 Animal experiments were approved by the Institutional Animal Care and Use 
Committee at the University of Szeged in accordance with the U.S. National Institutes of 
Health guidelines for animal care. 
 
6.2. Human studies: Patients and experimental design 
Healthy human hearts were obtained from organ donor patients (CONT, n=5) whose 
hearts were explanted but due to technical reasons (CMV infection, extensive damage during 
harvest and size donor / recipient mismatch), not used for transplantation. The donors did not 
present any important previous medical history or any abnormalities in ECG and 
echocardiography (LV dimensions/contractility within normal ranges); these organ donors 
had died from head trauma, cerebral or subarachnoid hemorrhage. Explanted end-stage failing 
hearts were obtained from patients with advanced heart failure of non-ischaemic (DCM) 
(n=5) or ischaemic aethiology (ICM) (n=5). Before transplantation the clinical state of all 
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patients was determined according to the New York Heart Association (NYHA) 
classification; patients of NYHA class III–IV underwent a clinical assessment that included 
resting electrocardiogram, echocardiography and hemodynamic measurements. Tissue 
samples of the right and left ventricular free walls (RV and LV, respectively) and the inter-
ventricular septum (S) were taken at the time of explantation (avoiding scarred, fibrotic, or 
adipose tissue, endocardium, epicardium or coronary vessels). The samples were rinsed 
immediately, blotted dry, frozen in liquid nitrogen and kept at − 80°C until further processing 
for RNA isolation and quantitative RT-PCR analysis. 
All procedures were in accordance with the ethical standards of the responsible 
committee on human experimentation (institutional and national) and with the Helsinki 
Declaration of 1975. Informed consent was obtained from all patients for being included in 
the study according to the protocol approved by the Local Ethics Committee (IK-NP-0021-
24/1426/14).  
 
6.3. Morphological and morphometrical analysis of mouse skeletal muscles 
For morphological analysis, 10µm serial cryostat sections were taken from the 
midbelly region of different muscles of both Cmpt and BALB/c mice followed by standard 
hematoxylin-eosin (HE) staining. Briefly, sections were fixed in -20°C acetone (for 5 min) 
then stained by hematoxylin for 5 min followed by 1% eosin for 1.5 min. After dehydration in 
isopropanol series (50-75-90-100%, 30s each) and toluol, samples were mounted with 
Entellan and covered with coverslips.  
By taking pictures from all microscopic fields, the whole cross-sectional area (CSA) 
of each muscle was reconstructed using the Cell B program (Olympus DP Soft software, 
Version 3.2., Soft Imaging System GmbH; Münster, Germany) and fiber number was 
determined by counting all fibers in TA, EDL and SOL muscles with the help of Digimizer 
software (MedCalc Software, Mariakerke, Belgium) (Fig. 7).  
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Figure 7. Steps of morphometrical analysis of skeletal muscles using Digimizer Software (MedCalc 
Software, Mariakerke, Belgium). 
 
6.4. Myosin heavy chain (MHC) immunohistochemistry of mouse skeletal muscles 
Fiber type analysis was carried out on serial cryosections of 10µm thickness of TA, EDL and 
SOL muscles from both Cmpt and BALB/c wild type male mice. Acetone-fixed sections were 
first washed with PBS, 
blocked in 5% non-fat milk 
powder in PBS (for 20 min), 
then incubated overnight at 
4°C with mouse monoclonal 
primary antibodies BA-D5, 
sc-71 and BF-F3 specific for 
myosin heavy chain (MHC) 
I (slow oxidative), MHCIIA (fast oxidative) and MHCIIB (fast glycolytic), respectively 
(Deutsche Sammlung von Mikroorganismen und Zellkulturen [DSMZ], Braunschweig, 
Germany) (Table 1).  
After incubation with the primary antibodies sections were washed in 5% non-fat milk 
powder in PBS for 10 min, incubated with the peroxidase-conjugated secondary antibody 
(rabbit anti-mouse, Dako, Denmark; Table 1) for 60 min and finally washed in PBS and Tris 
(20mM, pH7.5, 5 min each). Immunocomplexes were visualized by diaminobenzidine (DAB) 
staining (0.5mg/ml DAB, 0.006% H2O2 in 20 mM Tris buffer pH7.5). Nickel enhancement 
Specificity of Ab Name and type of Ab Dilution 
anti-MHC I BA-D5, mouse  monoclonal, purified 1:25 
anti-MHCIIA sc-71,  mouse monoclonal 1:25 
anti-MHCIIB BF-F3,  mouse monoclonal 1:5 
peroxidase-conjugated 
secondary antibody 
rabbit anti-mouse 
immunoglobulins 1:150 
Table 1. Primary and secundary antibodies (Ab) used for 
immunohistochemistry in mouse skeletal muscles. 
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(0.5mg/ml DAB, 0.15% Ni(NH4)2SO4, 0.006% H2O2 in 20 mM Tris buffer pH7.5) was used 
for MHCIIB immunohistochemistry to improve signal intensity. DAB reaction was stopped 
by PBS, then sections were dehydrated and mounted with Entellan.  
 IIX fibers were considered as those not stained by any of the above antibodies (Fig. 
8). The size and distribution of muscle fibers in SOL were determined by analyzing all (700-
800) fibers in each muscle by applying Cell B and Digimizer softwares, while in EDL 
muscles about 50% of the fibers (600 to 1100 fibers in BALB/c and Cmpt mice, respectively) 
were measured. In TA muscles, analysis of fiber size as well as fiber type distribution was 
carried out by examining 2-3 representative microscopic fields (with 10x objective; Figure 8) 
of both superficial and deep portions. Regional results were then summarized for the whole 
cross sectional area of each TA muscle (500 to 1000 fibers/muscle in 4-7 microscopic fields 
in BALB/c and Cmpt mice, respectively).  
 
Figure 8. Representative fiber types in TA muscle (deep region). Marked fibers are representative for IIB 
(red), IIX (lila) and IIA (yellow) fibers, respectively. 
 
6.5. Quantitative RT-PCR analysis of mRNA transcripts in mouse skeletal muscles and 
human heart samples 
6.5.1. RNA isolation 
Total RNA was isolated from TA muscles of Cmpt and BALB/c male mice (n=5) with 
TRI reagent (Molecular Research Center, Inc. Cincinnati, OH) or from the LV, S and RV 
samples of the CONT, DCM or ICM patients (n=5) with the acid guanidinium thiocyanate-
phenol-chloroform (AGPC) method (Chomczynski and Sacchi 1987). 
Both protocols included the following steps: homogenization, phase separation, RNA 
precipitation, washing and solubilization (Fig. 9). Homogenization of tissue samples were 
carried out in TRI reagent (1ml/50-100mg tissue) or in SolD (4M guanidine-thiocyanate, 
25mM sodium citrate buffer, 0.5% N-lauroylsarcosine, 0.1M mercaptoethanol) (0.5ml/50mg 
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tissue) using a glass/Teflon Potter homogenizer (at 600 and 800 rpm, 2 min each). 
Homogenates were stored for 5 min at room temperature to support complete dissociation of 
nucleoprotein complexes. Insoluble materials (polysaccharides, extracellular membranes and 
cell debris) were then removed by centrifugation at 12000g for 10 min at 4°C. Supernatant 
was transferred to fresh Eppendorf tubes. According to TRI reagent protocol, 0.2ml 
chloroform/ 1ml Tri reagent was used for phase separation while in case of AGPC method 
50µl sodium acetate (2M, pH4), 0.5ml phenol (saturated with diethyl-pyrocarbonate (DEPC)-
treated water) and 0.2ml chloroform-isoamylalcohol (24:1)/ 0.5ml SolD were applied for the 
same reaction. Samples were incubated on ice for 15 min followed by centrifugation (10000-
12000g, 15-20min, 4°C). The solution has been separated into a lower phenol-chloroform 
phase, an interphase and a colorless upper aqueous phase. RNA remained exclusively in the 
aqueous phase, whereas DNA and proteins were in the interphase and organic phase. The 
upper aqueous phase was carefully transferred to a new Eppendorf tube and RNA was 
precipitated by either isopropanol (0.5ml isopropanol/1ml TRI reagent) or 95% ethanol (1ml 
95% ethanol/ 0.5ml SolD) followed by centrifugation (10000-12000g, 10-20 min, 4°C). RNA 
precipitate formed a gel-like or white pellet on the side and bottom of the tube. After 
supernatant removal RNA pellet was washed by ethanol (1ml 75% ethanol/1ml TRI reagent 
or 0.2-0.5ml 70% ethanol/ 0.5ml SolD) followed by centrifugation (7500-10000g, 5-10min, 
4°C). Ethanol was removed carefully, while RNA was dried shortly and dissolved in RNAse-
free water (DEPC-treated).  
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Figure 9. RNA isolation protocols: comparison of TRI reagent-method with acid-guanidinium 
thiocyanate-phenol-chloroform (AGPC) method (Chomczynski and Sacchi 1987). 
RNA concentration and its purity were measured spectrophotometrically by NanoDrop 
(Thermo Scientific). Total RNA solution was essentially free of DNA and proteins and had a 
260/280 ratio of 1.8-2.0. Integrity of total RNA from both TA mouse muscles and human 
heart samples were controlled on 1% agarose gel stained by ethidium bromide; RNA proved 
to be undegraded (Figure 10).  RNA samples were kept at -80°C until further use. 
 
 
 
 
 
 
Figure 10. Representative ethidium-bromide 
stained gel (1% agarose) of total RNA isolated 
from TA (tibialis anterior) muscle of BALB/c 
and Cmpt male mice or from different human 
control heart regions.  LV (left ventricle), RV 
(right ventricle), S (septum), 28S, 18S, 5S: types of 
ribosomal RNA. 
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6.5.2. Reverse transcription 
Total RNA was isolated from tibialis anterior (TA) muscles of BALB/c and Cmpt 
mice and from the LV, S and RV regions of the CONT, DCM or ICM patients, followed by 
reverse transcription. The reaction mixture for cDNA synthesis (1µl oligo-dezoxythimidine 
(dT, Roche), 1µl dezoxy-nucleotide triphosphate (dNTP, Thermo Scientific), 1 or 2µg total 
RNA (mouse or human, respectively), DEPC water to 12.5µl) was denaturated at 65°C for 5 
min followed by cooling down the samples on ice for a few minutes. 4µl 5xMoloney Murine 
Leukemia Virus Reverse Transcriptase (MMLV-RT) buffer (Invitrogen), 2µl 0.1M DTT 
(Invitrogen), 0.5µl RNase Inhibitor (20U, Fermentas) and 1µl MMLV enzyme (Invitrogen) 
were added to each tube to a final volume of 20µl. cDNA synthesis was carried out at 37°C 
for 50 min, thereafter MMLV enzyme was inactivated at 70°C for 15 min. Samples were then 
DNAse-treated (Fermentas) in order to avoid genomic contamination of cDNA. cDNA 
samples were stored at -20°C until further use. 
6.5.3. qRT-PCR analysis  
For the detection of transcript 
levels of mouse MHCI, 
MHCIIA, MHCIIX and 
MHCIIB as well as human 
Mstn, ActRIIB, IGF-I, and IGF-
IR quantitative RT-PCR was  
carried out with SYBR GREEN  
master mix (Fermentas) on a Light Cycler 1.5 (Roche Applied Science). Since some of the 
genes generally used for internal normalization in qRT-PCR contain several pseudogenes 
(e.g. GAPDH, beta-actin) of which co-amplification may compromise their reliability as 
reference genes (Sun et al. 2012), hipoxanthine-guanine phosphorybosyltransferase 
(hprt/HPRT) has been used as a single internal control gene in our experiments. Indeed, 
hprt/HPRT expression did not significantly change between different mouse lines or heart 
regions of CONT and DCM or ICM patients. Cycle conditions were set as an initial 
denaturation step, followed by 45 cycles for template denaturation, annealing and extension 
phases (Table 2).  
Steps of qPCR Temp (°C) Time 
Initial denaturation phase 95 10min 
Amplification (45 cycles)   
Denaturation phase 95 10s 
Annealing phase 58 10s 
Extension phase 72 10s 
Table 2. qPCR amplification parameters 
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Specificity of the PCR products was confirmed by melting curve analysis followed by 
verification of amplicon length on 1.5 % agarose gels stained by ethidium bromide. Primer 
pairs for mouse Hprt, MHCI, MHCIIA, MHCIIX, MHCIIB as well as those for human Mstn, 
ActRIIB, IGF-I, IGF-IR and HPRT were designed to intron spanning exons by Primer 3 Input 
(version 0.40) software and tested to avoid primer dimers, unspecific amplification and self-
priming formation (Table 3). 
Target Accession number Forward primer Reverse primer Efficiency 
Product 
size (bp) 
MHCIIB 
mouse NM_010855.2 
GTGATTTCTCCTGT
CACCTCTC 
GGAGGACCGCAA
GAACGTGCTGA 2.000 280 
MHCIIX 
mouse NM_030679.1 
ACGGTCGAAGTTG
CATCCC 
CAGTAGTTCCGCC
TTCGGTC 1.870 272 
MHCIIA 
mouse NM_001039545.2 
TGCACCTTCTCGTT
TGCCAG 
GGCCATGTCCTCG
ATCTTGT 1.832 320 
MHCI 
mouse NM_003689292.1 
CTACAGGCCTGGG
CTTACCT 
TCTCCTTCTCAGA
CTTCCGC 1.702 126 
Hprt 
mouse NM_013556.2 
TCAGTCAACGGGG
GACATAAA 
GGGGCTGTACTG
CTTAACCAG 1.719 142 
Mstn 
human NM_005259.2 
TTCGTCTGGAAACA
GCTCCT 
CATTTGGGTTTTC
CATCCAC 1.783  220 
ActRIIB 
human NM_001106.3 
TGACTTTGGCTTGG
CTGTTC 
ATGTACTCATCCA
CGGGTCC 1.834 219 
IGF-I 
human XM_005268835.1 
ATGCTCTTCAGTTC
GTGTGTG 
GGGTCTTGGGCAT
GTCGGTG 1.758 219 
IGF-IR 
human NM_000875.3 
GACAACCAGAACT
TGCAGCA 
GATTCTTCGACGT
GGTGGTG 1.714 241 
HPRT 
human NM_000194.2 
TGCTCGAGATGTG
ATGAAGG 
TCCCCTGTTGACT
GGTCATT 2.044 192 
 
Table 3. Primer properties used in qRT-PCR. bp: base pair, MHC: myosin heavy chain; Mstn: myostatin, 
ActRIIB: activin receptor IIB, IGF-I: insulin-like growth factor I, IGF-IR: insulin-like growth factor I receptor, 
hprt and HPRT: hypoxanthine-guanine phosphorybosyltransferase. 
	  
6.6. Quantitative RT-PCR analysis of miRNA transcripts in human heart samples 
From the above detailed total RNA isolates of human heart samples, cDNA was 
synthetized and quantitative real-time PCR was performed with miRCURY LNATM Universal 
RT microRNA PCR kit (Exiqon, Denmark) on LightCycler®480 (Roche, Switzerland) 
according to the manufacturer’s instructions. Briefly, total RNA was diluted to a final 
concentration of 5ng/µl, and mixed with Reaction buffer and Enzyme mix provided with the 
kit in a final volume of 10µl. Reaction mixture was incubated for 60 min at 42°C, and reverse 
transcriptase was heat-inactivated for 5 min at 95°C. Then, cDNA was diluted to 80x and 4µl 
of diluted cDNA were mixed with 6µl of the PCR Master mix and PCR primer mix supplied 
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by the manufacturer. The primers for both microRNA-208b and control microRNA-103a-3p 
were designed and prepared by using Exiqon’s LNATM technology. Polymerase was activated 
for 10 min at 95°C, and microRNA-208b and microRNA-103a-3p were amplified and 
quantified (denaturation: 10 sec at 95°C; annealing/synthesis: 1 min at 60°C). The specificity 
of amplifications was assessed by melting curve analysis (42°C to 80°C) and by agarose gel 
electrophoresis (1%). At last, crossing point values (Cp) were calculated. MicroRNA-208b Cp 
values were normalized to the corresponding housekeeping microRNA-103a-3p Cp values. 
Then, all pairwise ΔCp value normalization was carried out to control ΔCp values, and 
expressed as mean of the three replicates of 2-ΔΔCp values (fold change). 
6.7. Statistical analysis 
Statistical analysis was performed by unpaired t test and one- way/two-way ANOVA 
or non-parametric t-test (Welch test) using Prism software (GraphPad Software, Inc.; San 
Diego, CA), as appropriate. All data were expressed as means±SEM. The level of p<0.05 was 
considered significant. The individual p-values are indicated in the figure legends.  
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7. Results 
7.1. Muscle phenotype of Compact mice  
7.1.1. Body- and muscle weight  
We compared 2.5-month-old Mstn mutant Cmpt mice with wild-type BALB/c mice in 
terms of body and muscle weight. Cmpt male mice were significantly larger than BALB/c 
regarding their body weight (Fig. 11A).  
 
Figure 11. Body weight (A) and normalized muscle masses (B, C) of BALB/c and Cmpt male mice. B-C 
show normalized muscle masses of quadriceps (Quadr), gastrocnemius (Gastro), tibialis anterior (TA), extensor 
digitorum longus (EDL) and soleus (SOL) muscles. Bars represent mean values±SEM, asterisks show significant 
differences between BALB/c and Cmpt mice (n=5-10, *p<0.05, ***p<0.001).  
 
Absolute weights of the different hindlimb muscles, such as Quadr, Gastro, TA, EDL 
and SOL muscles, were significantly larger in Cmpt mice (data not shown). Similarly, muscle 
weights normalized to body weights were significantly increased in Cmpt animals, with the 
exception of the oxidative SOL muscle. These results indicated a disproportionate increase in 
muscle masses in Cmpt mice (Fig. 11B-C). To assure that the 2.5-month-old Cmpt mice had 
already finished the intense growing phase, we compared body- and muscle (TA, EDL and 
SOL) weights in mice of different ages as well (Fig. 12). Body weight was similar in young 
(2.5-month-old) and adult (4- and 7-month-old) animals, while 12-23-month-old mice had 
slightly higher weight measurements. However, no significant difference was found in muscle 
weights amongst any of the age groups, indicating that the 2.5-month-old animals have 
already reached muscle size typical of adult mice.  
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Figure 12.  Body weight (A) and muscle masses of TA (B), EDL (C) and SOL (D) muscles of male Cmpt 
mice at different ages. Age of mice is given in months, bars represent mean values±SEM, asterisks show 
significant differences compared to 2.5-month-old Cmpt mice (n=4-10, *p<0.05). 
7.1.2. Muscle fiber number and fiber cross sectional area  
To define whether the hypermuscularity of Cmpt mice is caused by hyperplasia or 
hypertrophy, we analyzed muscle fibers on HE- or MHC-immunostained serial cross-sections 
of different muscle types in both mutant and wild-type animals (Fig. 13).  
 
 
Figure 13. Total muscle fiber number (A) and average fiber cross sectional area (CSA) (B) of TA, EDL 
and SOL muscles in BALB/c and Cmpt male mice. Bars represent mean values±SEM, asterisks show 
significant differences between BALB/c and Cmpt mice (n=3-5, *p<0.05, **p<0.01, ***p<0.001). 
 
Fiber number was significantly higher in all examined muscles of the 2.5-month-old 
Cmpt mice than that observed in wild-type mice. TA muscle revealed the most significant 
hyperplasia as compared with EDL and SOL muscles (Fig. 13A). However, fiber size did not 
differ in TA muscles between Cmpt and BALB/c mice. EDL and SOL muscles of Cmpt mice, 
on the other hand, showed clear evidence of hypertrophy as well (Fig. 13B). To control fiber 
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parameter alterations in Cmpt mice along with 
aging, we analyzed TA muscles of 7-month-old 
Cmpt mice and found no differences compared with 
2.5-month-old mice (Table 4).  
In summary, based on our results, hypermuscularity 
of Cmpt mice is characterized by fiber hyperplasia 
in TA muscle and by a combination of hyperplasia 
and different grades of hypertrophy in EDL and 
SOL muscles.  
 
 
7.1.3. MHC composition and fiber size distribution  
To analyze the possible effects of the Cmpt mutation on MHC composition, serial 
cryosections of TA, EDL and SOL muscles were immunostained using sets of monoclonal 
antibodies in order to differentiate type I, IIA, IIX and IIB fibers, respectively (Fig. 14-17).  
 
Figure 14. Representative immunohistochemical stainings of tibialis anterior (TA), extensor digitorum 
longus (EDL), and soleus (SOL) muscles of BALB/c (A) and Cmpt (B) male mice. Panel A represents whole 
cross-sectional areas of TA, EDL, SOL muscles stained either by MHCIIB antibody (in TA and EDL muscles) 
or by MHCI antibody (in SOL muscle) in BALB/c mice, and Panel B shows the same tissue staining for sections 
in Cmpt male mice. All muscles were stained by diaminobenzidine but Cmpt TA muscle was additionally nickel 
enhanced. Scale bars represent 400 µm for TA, 200 µm for EDL and 200 µm for SOL muscles. 
 
 
Cmpt Cmpt 
Age (in months) 2.5 7 
Muscle type TA TA 
Fiber number 
(mean ± SEM) 5455 ± 114 5450 ± 136 
Fiber size  
(mean ± SEM) 2114 ± 118 2193 ± 95 
Number of values 5 3 
Table 4. Muscle cellularity of TA muscles in 
2.5-month-old vs. 7-month-old male Cmpt 
mice. 
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In line with the literature (Bloemberg and Quadrilatero 2012), only MHCII isoforms 
were detected in TA and EDL muscles of both mouse lines (Fig. 14-17), whereas no MHCIIB 
fibers were found in SOL muscle. Therefore, we next analyzed the parameters of the slow-
type I and the fast-type IIA and IIX fibers in SOL muscle (Fig. 14-17).  
 
 
Figure 15. Immunohistochemical analysis of myosin heavy chain (MHC) isoforms in different regions of 
TA muscles of BALB/c and Cmpt male mice. A-C represent the superficial region of BALB/c mice while D-F 
depict that of Cmpt mice; G-I and J-L show BALB/c and Cmpt deep regions, respectively. HE staining (A,D,G,J) 
and antibodies against MHCIIA (B,E,H,K) and MHCIIB (C,F,I,L) were applied. Representative fibers are 
marked as IIA, IIB and IIX fibers. Scale bars represent 100 µm. 
 
30	  
	  
By counting different fiber types on whole cross sectional images, we noted that the 
fast-type TA muscles of Cmpt mice contained significantly more glycolytic IIB fibers while a 
decreased number of IIX and IIA fibers as compared with that in wild-type mice (Fig. 14, 15, 
16A). 
 
Figure 16. Fiber type composition (A-B) and mean fiber cross sectional area (C) in TA, EDL and SOL 
muscles of BALB/c and Cmpt male mice (mean±SEM). Panel A represents fiber type composition of all fibers 
in TA, EDL and SOL muscles, while panel B shows regional fiber type distribution of TA muscles subdivided 
into superficial and deep regions. Panel C represents mean fiber cross sectional area (CSA) of the different (I, 
IIA, IIX and IIB) fibers in TA, EDL and SOL muscles. Asterisks show significant differences between BALB/c 
and Cmpt mice (n=3-4, *p<0.05, **p<0.01, ***p<0.001) while double cross indicates significant changes 
between superficial and deep portions of the same TA muscle within a specific mouse line (n=3, #p<0.05). 
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 Fiber composition has been shown to be different in superficial and deep portions of 
TA muscles in wild-type mice, with more glycolytic IIB fibers at the periphery (Bloemberg 
and Quadrilatero 2012)). Therefore, we also compared the regional fiber type composition in 
both mouse lines (Fig. 15, 16B). The number of IIB fibers was significantly higher in both 
superficial and deep regions of Cmpt mice compared with that in wild-type animals (Fig. 15, 
16B). Moreover, both muscle regions contained similar number of IIB fibers, whereas in 
wild-type BALB/c mice, IIB fibers were abundant only in the superficial region, as expected 
(Fig. 15, 16B). In contrast, the proportion of the glycolytic-oxidative IIX fibers significantly 
decreased in both TA regions of Cmpt mice, without any regional difference in fiber number 
(Fig. 15, 16B). In wild type mice, however, we found a significantly higher proportion of IIX 
fibers in the deep region (Fig. 15, 16B). Finally, the low number of the oxidative IIA fibers 
were almost exclusively confined to the deep region of TA muscles in both mouse strains; 
however, the number of IIA fibers was further reduced in Cmpt mice (Fig. 15, 16B).  
Similar to TA muscles, the number of glycolytic IIB fibers was increased in the fast-
type EDL muscles of Cmpt mice, while the number of IIX and IIA fibers was significantly 
lower as compared with that of wild-type mice (Fig. 14, 16A). 
In contrast, the oxidative SOL muscles in Cmpt mice contained more slow-type I 
fibers and less fast-type IIA fibers than those in wild-type mice, while the number of IIX 
fibers was very low and not different in the two mouse lines (Fig. 14, 16A). 
Together, our findings clearly demonstrate a substantial shift toward a more glycolytic 
phenotype in the fast-type TA and EDL muscles but not in the mixed-type oxidative SOL 
muscles of Cmpt mice.  
In line with our results regarding average fiber size (Fig. 13B), we could not detect 
specific hypertrophy for any of the IIB, IIX or IIA fiber types in TA muscles (Fig. 16C). 
Indeed, size distribution of IIB, IIX and IIA fibers in TA muscle revealed only minimal 
changes in terms of peak position or shape of the histograms in Cmpt mice when compared to 
wild-type muscles (Fig. 17A). 
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Figure 17. Frequency distribution of MHCIIB, MHCIIX, MHCIIA and MHCI fiber size in TA (A), EDL 
(B) and SOL (C) muscles of BALB/c and Cmpt male mice. CSA: mean fiber cross-sectional area. 
 
 In EDL muscles, however, fiber hypertrophy (Fig. 13B) was exclusively detected in 
IIB fibers, while the size of IIX and IIA fibers were unchanged (Fig. 16C). In line with these 
findings, IIB fiber distribution in EDL muscles has been shifted toward larger fiber size in 
Cmpt mice, while IIX and IIA histograms were not different between the Cmpt and BALB/c 
lines (Fig. 17B). In contrast to fast muscles, both I and IIA fibers showed evidence of 
hypertrophy in SOL of Cmpt mice (Fig. 16C). Indeed, both fiber frequencies shifted toward a 
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size increase (Fig. 17C). Due to their low number, IIX fiber size was not analyzed in SOL 
muscles. 
7.1.4. mRNA levels of MHC isoforms  
In order to determine the transcript levels of MHC isoforms (ie. MHCI, IIA, IIB, IIX) 
we performed qRT-PCR analysis in TA muscles of both Cmpt and BALB/c male mice (Fig. 
18). 
 
Figure 18.  mRNA levels of MHC isoforms and hprt in TA muscles of BALB/c and Cmpt male mice. Bars 
in B-D represent mRNA levels of MHCII isoforms normalized to hprt transcripts (A) (mean±SEM, *p<0.05, 
**p<0.01, n=5).  
 
  Hprt was used as an internal control because Hprt levels were similar in Cmpt vs. 
wild-type TA muscles (Fig. 18A). We found that MHCIIB mRNA levels were significantly 
increased (Fig. 18B), while MHCIIX (Fig. 18C) and MHCIIA transcript levels (Fig. 18D) 
both decreased in Cmpt. The slow MHCI isoform was almost undetectable (data not shown). 
These results are in line with those obtained by immunohistochemical analysis, suggesting 
that the fiber-type shift in the TA muscle is regulated at the level of MHC transcription.  
7.2. Myostatin and IGF-I signaling in the human heart 
7.2.1. Study patients 
A detailed summary of the pre-transplant data and drug therapy of study subjects are shown in 
Table 5.  
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 CONT DCM ICM 
Number of samples 5 5 5 
Gender (female/male) 3/2 2/3 4/1 
Age (year) 29 ± 9 39 ± 10 57 ± 11*# 
NYHA functional class 
III/IV, n n.a. 0/5 3/2 
PAP, mmHg  n.a. 31.6 ± 4.7 30.8 ± 5.6 
PWP, mmHg n.a. 24 ± 4.3 21 ± 3.5 
LVED, mm  n.a. 68 ± 4 71 ± 4 
LVSD, mm n.a. 63 ± 5 61 ± 8 
PW, mm n.a. 9.5 ± 0.5 10 ± 1.5 
IVS, mm n.a. 10 ± 0.7 11 ± 1.5 
LVEF, % n.a. 16 ± 3 23 ± 3 
Medications    
ACE-inhibitor - ++ ++ 
β-Blocker - ++ ++ 
Diuretics - ++ ++ 
Digitalis - + + 
PDE-inhibitor - ++ ++ 
Dopamine/Noradrenaline ++ ++ + 
Statin  - - ++ 
Aspirin - - ++ 
Desmopressin  ++ - - 
 
Table 5. Clinical, echocardiographic and hemodynamic characteristics of DCM and ICM patients. Values 
are given in mean±SEM; *p˂0.05 compared to control; #p˂0.05 compared to DCM Abbreviations: CONT: 
healthy control individuals, DCM: dilated cardiomyopathy, ICM: ischemic cardiomyopathy, NYHA: New York 
Heart Association, PAP: mean pulmonary artery pressure, PWP: mean pulmonary wedge pressure, LVED: left 
ventricular end-diastolic diameter, LVSD: left ventricular end-systolic diameter, PW: posterior wall thickness, 
IVS: interventricular septum thickness, LVEF: left ventricular ejection fraction, ACE: angiotensin converting 
enzyme, PDE: phosphodiesterase, n.a.: not applicable   
 
Both female and male patients were included in all groups. The age of ICM patients differed 
as expected significantly from both CONT and DCM, since ICM patients are usually 
diagnosed with end-stage heart failure later than DCM patients. DCM and ICM patients were 
in either NYHA class III or IV with no difference in pulmonary artery pressure (PAP, PWP) 
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left ventricle size parameters (LVED, LVSD, IVS, PW) or left ventricular ejection fraction 
(LVEF) among groups. Extra care was taken to exclude diabetic (insulin-treated) patients 
from the study to avoid possible modification of the IGF-I signaling by insulin treatment. All 
patients were managed with angiotensin-converting enzyme (ACE)-inhibitors, beta-blockers 
and diuretics, however, aspirin and statins were only used in case of ICM patients. CONT 
subjects received iv. treatment composed of very low catecholamine infusion (noradrenaline: 
01.-0.2 µg/kg/min, dopamine: 1-2 µg/kg/min) whereas adequate fluid balance was maintained 
with intravenous fluids including colloids (e.g. Voluven - hydroxyethyl starch) and 
Desmopressin. 
7.2.2. Myostatin and IGF-I signaling in healthy human control hearts 
So far, no comprehensive study has been carried out to reveal gene expression of the 
growth regulators Mstn and IGF-I and their receptors in different regions of healthy human 
hearts. In the present work we detected no significant difference in Mstn (Fig. 19A) and 
ActRIIB (Fig. 19B) transcript levels nor in Mstn signaling index (Fig. 19C) between septum 
(S), left ventricle (LV) and right ventricle (RV), however, Mstn levels showed decreasing 
tendency in the RV (Fig. 19A). In contrast, both IGF-I mRNAs (Fig. 19D) and IGF-I 
signaling index (Fig. 19F) followed an increasing tendency in RV accompanied with a 
significantly higher IGF-IR levels compared to those of LV (Fig. 19E). 
As a consequence, the ratio of Mstn/IGF-I gene expression (Fig. 20A) as well as those 
of ActRIIB/IGF-I receptors (Fig. 20B) and finally, the ratio of Mstn to IGF-I signaling (Fig. 
20C) all showed significantly higher values in LV/S as compared to RV. 
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Figure 19. Gene expression levels of Mstn and IGF-I as well as their receptors ActRIIB and IGF-IR 
normalized to HPRT in the septum (S), left ventricles (LV) and right ventricles (RV) of control (CONT)-, 
DCM-, and ICM hearts, respectively. Bars represent normalized Mstn- (A), ActRIIB- (B), IGF-I- (D), and 
IGF-IR- (E) transcript levels. Panel C shows ‘Mstn signaling index’ (Mstn multiplied by ActRIIB mRNA levels) 
while panel F represents ‘IGF-I signaling index’ (IGF-I multiplied by IGF-IR mRNA levels). Data are expressed 
in mean±SEM, asterisks show significant differences (n=5, *p˂0.05, **p˂0.01). 
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Figure 20. Growth factor ratio of Mstn/IGF-I (A), receptor ratio of ActRIIB/IGF-IR (B) and ‘Mstn/IGF-I 
signaling index’ (C) in the septum (S), left ventricles (LV) and right ventricles (RV) of control (CONT)-, 
DCM-, and ICM hearts, respectively. Panel C represents the ratio of Mstn and IGF-I signaling referred to as 
‘Mstn/IGF-I signaling index’ (‘Mstn signaling index’ divided by ‘IGF-I signaling index’ (Mstn x 
ActRIIB)/(IGF-I x IGF-IR)). Data are expressed in mean±SEM, asterisks show significant differences (n=5, 
*p˂0.05, **p˂0.01, ***p˂0.001). 
These data clearly demonstrate that Mstn signaling dominates over IGF-I in the LV more than 
in RV of healthy human hearts. 
7.2.3. Myostatin and IGF-I signaling in DCM patients compared to healthy controls 
In DCM patients we measured massive upregulation of Mstn mRNA (Fig. 1A) 
associated with an increased Mstn signaling index (Fig. 19C) in all heart regions compared to 
CONT, although ActRIIB levels remained relatively unchanged (Fig. 19B). Similar to healthy 
hearts, we found a significant upregulation of IGF-I transcripts (Fig. 19D) as well as of IGF-I 
signaling index (Fig. 19F) in RV of the failing hearts when compared to those of S, although 
IGF-IR expression did not show significant difference in either region nor in comparison to 
CONT hearts (Fig. 19E). Thus, the ratio of Mstn/IGF-I mRNA levels (Fig. 20A) and the 
Mstn/IGF-I signaling index (Fig. 20C) proved to be significantly higher in the left versus right 
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side of the DCM hearts and showed much higher levels than those of the CONT regions. 
Since the ratio of the ActRIIB/IGF-I receptors (Fig. 20B) did not change significantly we can 
conclude that Mstn was upregulated in all regions of failing hearts in DCM patients as 
compared to CONT. However, given the higher IGF-I levels in RV, left and right side of 
failing heart differed significantly from each other in regard to the ratio of Mstn/IGF-I 
signaling similar to those of healthy ones (Fig. 20C). 
7.2.4. Myostatin and IGF-I signaling in ICM patients compared to healthy controls 
In contrast to DCM patients, we could not detect any difference in either Mstn (Fig. 
19A) or ActRIIB transcript levels (Fig. 19B) or in Mstn signaling index (Fig. 19C) in any 
heart region of ICM patients compared to those of CONT. Similarly, IGF-I (Fig. 19D) and 
IGF-IR levels (Fig. 19E) as well as IGF-I signaling index (Fig. 19F) did not differ in ICM 
heart regions; however, in comparison to CONT, IGF-I showed a decreasing tendency of 
expression in the RV, while increased expression of IGF-IR in the LV was present. 
Consequently, both ratios of Mstn/IGF-I (Fig. 20A) and ActRIIB/IGF-IR (Fig. 20B) were 
similar in all analyzed regions of ICM hearts. However, significantly higher Mstn/IGF-I ratios 
were revealed in RV due to decreased IGF-I levels as well as significantly lower 
ActRIIB/IGF-IR ratios in LV when compared to CONT hearts (due to increased IGF-IR 
levels). In summary, ICM hearts did not show significantly altered modulation of Mstn 
signaling in either heart region, whereas IGF-I signaling, in contrast to the healthy situation, 
seemed to be moderately induced in the LV, while inhibited in the RV. 
7.2.5. Differences in Myostatin/IGF-I signaling between DCM and ICM patients 
Based on our results, all regions of DCM hearts showed significantly higher Mstn 
levels (Fig. 19A) as well as elevated Mstn signaling index (Fig. 19C) than those of ICM 
hearts. Moreover, ActRIIB (Fig. 19B) also revealed increased levels in LV of DCM vs. ICM 
patients. Nevertheless, we found no significant difference in IGF-I signaling on the left side of 
failing hearts (Fig. 19D-F), although significantly less IGF-I transcripts were evident on the 
right side of ICM hearts in comparison with that of DCM ones (Fig. 19D). As a consequence, 
all parameters describing the ratio of Mstn to IGF-I signaling (Fig. 20A-C) showed 
significantly increased values in the LV of DCM versus ICM hearts. Although in the RV we 
have revealed similar signaling ratio in both types of failing hearts (Fig. 20A-C) the reason for 
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that was an upregulation of Mstn signaling in DCM patients while a downregulation of IGF-I 
signaling in ICM heart samples.  
7.2.6. miR-208 in relation to myostatin expression in DCM and ICM patients compared 
to healthy controls 
In parallel with the massive upregulation of Mstn mRNA in the LV of DCM patients 
we measured a mild upregulation of miR-208b (1.505 fold change) compared to CONT. A 
similar but less pronounced upregulation was seen in ICM hearts (1.405 fold change) when 
compared to CONT, however, no significant difference was detected between DCM and ICM 
patients (Table 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Left ventricle CONT DCM ICM 
miR-208b 
(mean ± SEM) 1 ± 0.19 1.505 ± 0.26 1.405 ± 0.24 
Number of values 5 3 4 
Table 6. miR-208b expression level in left ventricle region 
of human heart. CONT: control, DCM: dilated 
cardiomyopathy, ICM: ischemic cardiomyopathy. 
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8. Discussion 
Mstn belongs to the TGF-β family and is a negative regulator of skeletal muscle 
growth. However, it plays also a crucial role in governing heart growth, metabolism and 
contraction. Our aim was to describe different aspects of Mstn signaling in skeletal muscle 
and heart tissue. To this end, two different model systems have been used in our experiments, 
(i) the Mstn propeptide-mutant Cmpt mice as well as (ii) healthy and pathological human 
hearts (S, LV, RV samples of DCM and ICM patients). Muscle cellularity and fiber type 
distribution have been analyzed in the fast TA and EDL as well as the mixed-type SOL 
muscles of Cmpt mice and transcript levels of MHC isoforms were quantified by qPCR. On 
the other hand, gene expression of Mstn and IGF-I, the two major but mostly counter-acting 
regulators of cardiac tissue have been investigated in different regions of healthy or 
pathological human hearts by measuring transcript levels of Mstn, ActRIIB, IGF-I, IGF-IR 
and miR-208, the negative posttranscriptional regulator of Mstn. 
8.1. Muscle phenotype of Cmpt mice 
The Cmpt mouse line takes a special place in the group of hypermuscular animals carrying 
naturally occurring Mstn mutations, as the propeptide region, not the biologically active 
domain of Mstn is affected. Abnormal propeptide structure might play an important role in 
misfolding, inefficient secretion, and/ or abnormal processing of Mstn in Cmpt mice (Szabó et 
al. 1998). It has also been shown that the Cmpt mutation of Mstn is an indispensable yet not 
satisfactory requirement for the full expression of the hypermuscular phenotype, pinpointing 
the potential significance of additional modifier genes (Varga et al. 1997, 2003, 2005).  
Since the genetic background of the Cmpt mice is very complex and no appropriate genetic 
control line was available at the time of our experiments, we decided to analyze BALB/c mice 
as a control for the following reasons: i) This inbred line was used for mapping the Mstn 
mutation and the modifier genes in Cmpt mice (Szabó et al. 1998). ii) BALB/c mice are 
generally used as wild-type controls and their muscle parameters as well as fiber composition 
have already been reported (Freitas et al. 2002; Luedeke et al. 2004). iii) Muscle 
characteristics of BALB/c mice are similar to those of C57BL/6, another wild-type mice used 
as a genetic background for Mstn KO mice (McPherron et al. 1997), suggesting that these 
lines might be comparable to some extent (Luedeke et al. 2004; Pellegrino et al. 2005; 
Bloemberg and Quadrilatero 2012; McKeehen et al. 2013).  
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In the present study we show, in accordance with others (Bünger et al. 2004; Rehfeldt et al. 
2005; Amthor et al. 2007, 2009) that body- and muscle weights of male Cmpt mice are higher 
than those of wild type BALB/c mice. Body mass is even higher in Cmpt mice (47,7g) than in 
male Mstn KO of the same age (38-41g, McPherron et al. 1997). However, muscle weights 
normalized to body weight are comparable in both Mstn mutant lines, suggesting that Cmpt 
and Mstn KO mice represent a similar grade of muscularity. One exception was the soleus 
muscle, which seemed to be different in this regard, as its relative muscle-to body weight did 
not increase in Cmpt compared with the wild type mice. Indeed, it has previously been 
reported that the oxidative soleus muscle contained less Mstn transcript than the glycolytic 
EDL (Mendler et al. 2000; Wang et al. 2012) and, that the lack of Mstn had stronger effect on 
glycolytic muscles than on oxidative ones (McPherron et al. 1997; Carlson et al. 1999; 
Hennebry et al. 2009; Wang et al. 2012). Therefore, we analyzed three different hindlimb 
muscles: the fast-glycolytic TA and EDL as well as the oxidative SOL muscles in Cmpt mice. 
Based on extensive morphometrical analysis - measuring and counting all fibers on HE 
stained cross sections or 500-1000 fibers on MHCIIB-stained sections - TA muscles were 
exclusively characterized by muscle fiber hyperplasia, with no obvious hypertrophy (Fig. 21).  
 
Figure 21. Summary of muscle morphometrical and immunohistochemical results in myostatin mutant 
Cmpt mice. Arrows show increase or decrease in specific fiber types and MHC (myosin heavy chain) transcript 
levels. TA: m. tibialis anterior, EDL: m. extensor digitorum longus, SOL: m. soleus. 
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This observation may somewhat be surprising, as previous reports described both hyperplasia 
and hypertrophy in different Mstn KO animals (McPherron and Lee, 1997; Amthor et al. 
2009). However, even in the original Mstn KO mouse study (McPherron et al. 1997), the ratio 
of hyperplasia to hypertrophy varied in different muscles, e.g. the TA muscles of Mstn KO 
mice were dominated by hyperplasia, while only 14% fiber hypertrophy was documented. To 
note, Mstn KO vs. Mstn+/+ control mice (McPherron et al. 1997) contained similar fiber 
number in TA muscles (5470 vs. 2936) as the Cmpt vs. BALB/c mice in our study (5455 vs. 
3093), making KO and Cmpt experiments comparable. In contrast to TA, EDL muscles of 
Cmpt mice were characterized by a combination of hyperplasia (50%) and hypertrophy 
(20%), whereas EDL in the Mstn KO mice showed only a moderate hyperplasia and a 
stronger hypertrophy (Amthor et al. 2009) (Fig. 21). Amthor and colleagues (2009) compared 
EDL muscles of the Mstn KO with that of the female ‘Berlin’ Cmpt mice (BEHc/c). In line 
with our findings, they also detected stronger hyperplasia in female BEHc/c EDL muscles 
(1589) than in the Mstn KO (1200). In addition, fiber number of both BEH+/+ and Mstn+/+ 
controls were comparable with ours (1083 and 1160 vs. 1232, respectively). However, our 
results are somewhat different from those of BEHc/c females, in which fiber hypertrophy was 
very pronounced and dominated over hyperplasia (Amthor et al. 2009). We found that the 
moderate fiber hypertrophy in Cmpt EDL confined to the most glycolytic IIB fibers and was 
not present in IIX or IIA fibers (Fig. 21). This is again in accordance with the previous reports 
on a stronger effect of Mstn on glycolytic muscles (McPherron et al. 1997; Carlson et al. 
1999; Hennebry et al. 2009; Wang et al. 2012). We believe that the long separation of the 
‘Berlin’ and Hungarian Cmpt lines, gender differences, the use of different controls as well as 
our detailed sample analysis (counting 3000/1800 fibers in Cmpt/BALB/c vs. 150/180 fibers 
in BEHc/c /BEH+/+ (Amthor et al. 2009)) may account for these differencies.  
In the oxidative SOL muscle of Cmpt mice, low-grade hyperplasia (15%) and mainly 
hypertrophy (27%) accounted for the moderately higher muscle mass (Fig. 21). Moreover, 
both the oxidative I and IIA fibers showed hypertrophy compared with the wild-type control. 
The changes in SOL are different from those of fast TA and EDL muscles in the Cmpt line. 
Intriguingly, controversial results have been published regarding SOL in Mstn KO mice, 
where either 32% hyperplasia (Girgenrath et al. 2005), or 20% fiber hypertrophy has been 
described (Gentry et al. 2011). 
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It is not known so far, how cellularity in different muscle types is regulated upon Mstn defect. 
However, prenatal hyperplasia seems to be the major effect of developmental Mstn deficiency 
in most muscles of mice and cattle (McPherron et al. 1997; Grobet et al. 1997; Lee and 
McPherron 1997). Based on the different ratio of hyperplasia to hypertrophy in various Mstn 
deficient muscles, Mstn might have a strong, but muscle-type dependent effect on 
proliferation of muscle precursor cells. Consequently, postnatal fiber hypertrophy might be 
restricted to different grade. Rehfeldt and co-workers (2005) introgressed the Mstn mutant 
Cmpt allele into a special high growth mouse line (DUHi) and detected exclusively 
hyperplasia, similar to our results, in the predominantly fast rectus femoris and longissimus 
dorsi muscles. These data suggest that, at least in fast muscles, hyperplasia is even more 
pronounced in Cmpt than in Mstn KO mice. This difference might reside in the allelic 
variation of Mstn defect and/or in modifier genes influencing Cmpt phenotype. To prove that 
the dominance of hyperplasia (over hypertrophy) in 2.5-month-old Cmpt muscles is not the 
consequence of postnatal delay in fiber growth, we have analyzed TA muscles of 7-month-old 
Cmpt male mice. We found a similar hyperplasia without any substantial fiber hypertrophy in 
older animals as well, which refutes the idea that fiber growth might reach its peak later in 
adulthood. 
Although TA and EDL muscles contain predominantly type II glycolytic fibers (Bloemberg 
and Quadrilatero 2012), we observed a significant glycolytic shift within type II fibers in 
Cmpt mice. This result is consistent with that of Rehfeldt et al. (2005) who found more 
glycolytic fibers in the rectus femoris muscle of the special Cmpt-DUHi line by NADH-
tetrazolium reductase staining. A substantial glycolytic shift has also been described in EDL 
muscles of Mstn KO mice as well as in double-muscled cattle by applying different methods 
(ATPase and SDH staining vs. immunohistochemical analysis), which suggests that both 
metabolic and structural protein changes occur upon Mstn deficiency (Wegner et al. 2000; 
Girgenrath et al. 2005; Amthor et al. 2007). However, immunohistochemical staining of MHC 
isoforms is more appropriate to distinguish between fiber types. We have detected 
significantly more IIB fibers and less IIX or IIA fibers in TA muscles of Cmpt mice than in 
the wild type. Additionally, we analyzed fiber type distribution in both superficial and deep 
portions of TA, since regional differences in glycolytic fiber distribution are well-known in 
wild-type mice (Bloemberg and Quadrilatero 2012). Interestingly, the regional difference 
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disappeared in Cmpt mice, so that both superficial and deep regions of TA muscles were 
dominated by the glycolytic IIB fibers of a quite uniform fiber size. Transcript levels were in 
agreement with our immunohistochemical results; MHCIIB mRNA levels were significantly 
higher, while those of MHCIIX and IIA significantly lower in Cmpt TA muscles compared 
with those genes in wild type muscles. These findings suggest that the glycolytic fiber-type 
shift in fast muscles is supported by respective changes of MHC transcripts.  
Along this line, we measured the same ratio of IIB/IIX/IIA fibers in EDL muscles of Cmpt by 
using immunohistochemical methods. Amthor and colleagues (2007) demonstrated similar 
consequencies in regard to glycolytic shift in Mstn KO mice. Consistently, decrease in 
mitochondrial content, reduced expression of cytochrome c oxidase, lower citrate synthase 
activity and shortening of contraction as well as relaxation time have been described in Mstn 
KO mice (Amthor et al. 2007; Savage and McPherron 2010). Moreover, Mstn KOs showed 
impaired tolerance to chronic repetitive contractions (Ploquin et al. 2012) and a decrease in 
specific force generation, similar to what was measured in BEHc/c female EDL muscles 
(Amthor et al. 2007). Altogether, these data suggest that the function of the bigger and more 
glycolytic muscles is impaired upon Mstn defect. 
However, the oxidative SOL muscle has not shown any glycolytic shift in Cmpt mice (53% 
slow-oxidative type I fibers, 44% fast-oxidative IIA fibers) as compared with BALB/c line 
(38% type I fibers, 60% type IIA fibers). In contrast, these fibers were even more oxidative 
than the controls. Fiber type composition of BALB/c SOL in our experiments were in 
agreement with previous data (Freitas et al. 2002; Luedeke et al. 2004) and represented a fiber 
ratio typical of a wild-type SOL, with less than 40% slow-type I fibers (Pellegrino et al. 2005; 
Bloemberg and Quadrilatero 2012; McKeehen et al. 2013). Therefore, it is unlikely that 
BALB/c mouse was not an appropriate type of control for our experiments in this regard. 
Based on literature search, more than 50% slow-type I fibers in Cmpt animals is rather 
unusual for a SOL muscle in any type of mice, and also contradicts previous reports on Mstn 
KO mice (Girgenrath et al. 2005; Gentry et al. 2011; Wang et al. 2012). To conclude, 
different mechanisms of Mstn deficiency -with or without the influence of modifier genes- 
may induce differential and muscle-specific effects.  
In summary, Cmpt mouse, inspite of its complex genetic background, shows similarities (at 
least in fast muscles) to Mstn KO mice in terms of muscle cellularity and glycolytic muscle 
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phenotype, suggesting that the lack of Mstn is responsible for these morphological/functional 
changes. However, based on the more pronounced hyperplasia in Cmpt fast muscles as well as 
the different cellularity and oxidative phenotype of Cmpt SOL, additional studies are needed 
to elucidate the molecular mechanisms of Mstn inactivity and the possible role of modifier 
genes in Cmpt mice. 
8.2. Myostatin and IGF-I signaling in the human heart 
Mstn and IGF-I both have been shown to play a crucial role in the pathomechanism of human 
heart failure with upregulated Mstn protein in the failing myocardium (George et al. 2010). 
However, the exact mechanism and their possible interplay in the course of heart failure have 
not been clarified yet. In this study, we have measured Mstn, ActRIIB, IGF-I, IGF-IR 
transcript levels in different heart regions of normal and pathological human hearts, as well as 
the miR-208 expression serving as a negative regulator of Mstn expression. In order to 
characterize Mstn and IGF-I signaling we created complex parameters by combining 
respective transcript levels. 
In the present comprehensive qRT-PCR study we have found that Mstn dominated over IGF-I 
signaling much more in the LV than in the RV of healthy human hearts, and that DCM hearts 
upregulated Mstn expression in contrast to ICM hearts. This is the first demonstration that 
Mstn/IGF-I signaling differs in LV and RV in healthy hearts and shows significant alterations 
in end-stage heart failure due to DCM and ICM (Fig. 22).  
 
Figure 22. Summary of gene expression alterations regarding myostatin and IGF-I signaling in healthy 
human hearts as well as in DCM and ICM patients, respectively. Bigger circles represent higher expression 
of the signaling molecules in healthy vs. dilated cardiomyopathic (DCM) or ischemic cardiomyopathic (ICM) 
hearts or in left vs. right side of the hearts. Mstn: myostatin, IGF-I: insulin-like growth factor I, LV: left 
ventricle, S: septum, RV: right ventricle. 
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Several studies exist in the literature, indicating the presence and/or de-regulation of both 
Mstn and IGF-I under different conditions in the heart, however, the majority of data were 
collected from whole hearts or separately, from the LV (Sharma et al. 1999; Serneri et al. 
1999, 2001; George et al. 2010). Regarding Mstn expression in healthy hearts, only one study 
has been published so far on higher transcript levels of Mstn in LV as compared to RV in 
young piglet hearts (Torrado et al. 2010). In line with these data we have demonstrated here 
an obvious reciprocal regulation of Mstn and IGF-I in LV compared to RV characterized by 
elevated ratios of both Mstn/IGF-I and ActRIIB/IGF-IR transcripts in healthy human LV (Fig. 
22). Septum (S) samples, as being part of LV from the functional point of view, revealed 
similar values to those of LV in most cases. We assume that cardiomyocyte growth in LV/S 
should be balanced more tightly by growth inhibitors (i.e. Mstn) than that of RV since LV is 
exposed to higher-pressure overload, while RV to a relatively higher-volume overload. In 
addition to Mstn and IGF-I, several other factors have been reported to be enriched in either 
LV or RV; their asymmetric expression might reflect a molecular predisposition of 
myocardium to LV-concentric or RV-eccentric remodeling during postnatal development 
(Torrado et al. 2010; Modesti et al. 2004). Similarly, higher expression levels in LV versus 
RV have been demonstrated for cytochrome c oxidases and PGC1α, both of which are known 
to contribute to maintain mitochondrial function and oxidative metabolism (Zungu et al. 
2008). Recently, it has been shown that Mstn plays an important role in the regulation of 
oxidative metabolism of the myocardium (Biesemann et al. 2014). Therefore our results 
support the idea that the elevated ratio of Mstn/IGF-I signaling is an important regulatory 
mechanism under physiological conditions maintaining higher workload and oxidative 
metabolism in the LV. These results are also in accordance with the glycolytic shift in skeletal 
muscles upon Mstn defect and suggest that Mstn exert similar metabolic effects in both 
skeletal muscle and cardiac tissues, at least in the LV. 
In human failing hearts (in whole hearts or LV), Mstn protein activation was reported to be 
accelerated in both DCM and ICM patients (George et al. 2010). In parallel with this 
observation several groups found increased serum levels of Mstn protein in patients suffering 
from heart failure, although no correlation was demonstrated with the severity or type of 
cardiac disease (George et al. 2010; Heineke et al. 2010; Gruson et al. 2011; Breitbart et al. 
2013). One should also consider that elevated serum Mstn levels in cardiomyopathic patients 
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might be a combined effect of increased secretion from both cardiac and skeletal muscles. 
Nevertheless, exercise training lead to a reduction of Mstn levels only in skeletal muscles but 
not in serum of patients with chronic heart failure (Lenk et al. 2012).  Intriguingly, it has not 
been clarified, whether protein activation in failing heart is regulated either at the level of 
gene expression or posttranscriptionally. Here we show that DCM hearts are indeed 
characterized by upregulated Mstn transcripts in both LV/S and RV supporting the previous 
reports on protein activation in LV (George et al. 2010). However, we could not detect any 
significant elevation of Mstn transcript levels in ICM patients (Fig. 22). We also tested the 
miRNA-dependent posttranscriptional regulation of Mstn. miR-208 have been reported to be 
a negative regulator of Mstn expression (Callis et al. 2009), and to be upregulated in various 
forms of cardiomyopathy (Bostjancic et al. 2010; Satoh et al. 2010) and myocardial ischemia 
(Varga et al. 2014). In line with these, we detected a mild upregulation of miR-208b in the LV 
of DCM patients characterized by massive increase of Mstn transcripts that might suggest an 
adaptive counter-regulatory mechanism fine-tuning the expression of Mstn during heart 
failure. Since we have found no difference in miR-208b expression between DCM and ICM 
hearts, it is likely that increased Mstn mRNA is mainly regulated at the level of transcription. 
Although alterations in Mstn gene expression are followed by similar changes at the protein 
level in most cases (Shyu et al. 2006; McKoy et al. 2007; Lenk et al. 2009), the intra- or 
extracellular proMstn-pool might be posttranslationally activated by the cleavage of the 
propeptide (Mendler et al. 2000, 2007; Anderson et al. 2008). Thus, ICM patients might have 
a Mstn activation at the protein level (George et al. 2010), however, not at the level of 
transcription, whereas DCM hearts react with significant upregulation of Mstn transcripts. 
Similar to the results of George et al. (2010) we detected lower level of ActRIIB in ICM than 
in DCM patients, but this occured only in the LV. On the other hand, IGF-I expression was 
shown to be dynamically regulated in the course of heart failure as an important 
compensatory mechanism; however, conflicting data exist in the literature with both down- 
and upregulated IGF-I levels in end-stage heart failure (Serneri et al. 1999; Barton et al. 2005; 
Pucci et al. 2009). We could confirm significant decrease of IGF-I signaling in the RV of 
ICM patients but not in LV or DCM patients. Moreover, DCM patients still maintained the 
physiological difference in Mstn/IGF-I signaling ratios in LV versus RV, whereas no 
asymmetric gene expression pattern was detected in ICM patients (Fig. 22). The mechanisms 
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leading to different regulation of growth factor signaling in DCM and ICM patients remain to 
be clarified, however, it might relate to the different pathomechanism of heart failure and/or 
alternative regulation of compensatory mechanisms. Indeed, Mstn upregulation detected in 
DCM hearts might be part of adaptation reactions since Biesemann et al (2014) have recently 
reported that acute cardiac-specific deletion of Mstn in adult mouse hearts induces dilated 
cardiomyopathy followed by a massive compensatory up-regulation of Mstn in non-
cardiomyocytes. It is known, however, that various cardiac disease conditions, i.e. hypoxia 
can result in an imbalance of chamber-associated gene expression in myocardium (Chugh et 
al. 2003; Modesti et al. 2004; Zungu et al. 2008; Torrado et al. 2010). Therefore, ICM hearts 
of ischemic origin might not be able to compensate as effective as do DCM patients by 
upregulating Mstn to maintain oxidative metabolism (Biesemann et al. 2014) and by 
regulating their IGF-I signaling to counteract decreased contractility (Serneri et al. 1999). 
However, further research is needed to elucidate the physiological and pathological relevance 
of the complex Mstn/IGF-I network in human heart. 
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9. Conclusions 
We have described different aspects of Mstn signaling in skeletal muscle and heart tissue by 
applying two different model systems (i) the Mstn mutant hypermuscular Cmpt mice and (ii) 
healthy and pathological human hearts.	  
1. We have morphologically analyzed different glycolytic (TA, EDL) versus oxidative (SOL) 
skeletal muscles of Cmpt mice. All of them were significantly larger characterized by fiber 
hyperplasia of various grade. Fiber hypertrophy was either not present (TA) or confined to a 
specific type (IIB fibers in EDL) or in contrast, present in all fibers (SOL). These findings 
imply for muscle-specific morphological effects of Mstn defect in Cmpt mice. 
2. Fast-type glycolytic muscles (TA, EDL) of Cmpt mice contained significantly more 
glycolytic IIB fibers as well as increased MHCIIB transcript levels. According to previous 
reports, similar glycolytic shift was observed in Mstn KO mice suggesting that the lack of 
Mstn might be responsible for these changes in both Cmpt and Mstn KO mice. However, the 
genetic background (modifier genes) might also have an impact, since the oxidative SOL 
muscle in Cmpt mice did not display any glycolytic alteration. 
3. According to our human heart study we have found, that Mstn dominated over IGF-I 
signaling much more in the LV than in the RV of healthy human hearts. The spatial 
asymmetry in the expression pattern of Mstn/IGF-I is likely to play a role in the different 
growth regulation of LV versus RV.   
4. We identified Mstn as a massively up-regulated gene in DCM but not in ICM as part of 
potential compensatory mechanisms in the failing heart. 
5. Mild upregulation of miR-208b in pathological human hearts might serve as a Mstn 
counter-regulatory mechanism. Since miR-208b expression was similar in DCM and ICM 
hearts, higher levels of Mstn mRNAs in DCM might be maintained through accelerated 
transcription. 
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1. Introduction
Myostatin, also known as growth/differentiation factor 8 
(GDF-8) is a member of the transforming growth factor 
(TGF)-β superfamily and has been shown to be a negative 
regulator of skeletal muscle growth. The myostatin knock-
out (KO) mouse (McPherron et al. 1997) shows a hypermu-
scular phenotype similar to that of several different 
organisms (cattle, dog, pig, sheep, human) carrying natu-
rally occurring mutations of myostatin (McPherron and 
Lee, 1997; Schuelke et al. 2004; Clop et al. 2006; Mosher 
et al. 2007; Stinckens et al. 2008). Most of the natural muta-
tions result in an inactive protein caused by either an early 
STOP codon or a frameshift mutation in the bioactive 
domain of myostatin (McPherron and Lee, 1997; Mosher 
et al. 2007, Boman et al. 2009). One report details that 
missplicing of the myostatin pre-mRNA was responsible 
for hypermuscularity observed in a human infant (Schuelke 
et al. 2004). In contrast, another mechanism of myostatin 
inactivation induces the hypermuscular phenotype of the 
Compact (Cmpt) mice, which was originally selected for 
high protein content and body weight in the Technical 
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Summary
Myostatin is an important negative regulator of skeletal muscle growth. The hypermuscular Compact (Cmpt) mice carry a 
12-bp natural mutation in the myostatin propeptide, with additional modifier genes being responsible for the phenotype. 
Muscle cellularity of the fast-type tibialis anterior (TA) and extensor digitorum longus (EDL) as well as the mixed-type 
soleus (SOL) muscles of Cmpt and wild-type mice was examined by immunohistochemical staining of the myosin heavy 
chain (MHC) proteins. In addition, transcript levels of MHC isoforms were quantified by qPCR. Based on our results, all 
investigated muscles of Cmpt mice were significantly larger compared with that of wild-type mice, as characterized by fiber 
hyperplasia of different grades. Fiber hypertrophy was not present in TA; however, EDL muscles showed specific IIB fiber 
hypertrophy while the (I and IIA) fibers of SOL muscles were generally hypertrophied. Both the fast TA and EDL muscles 
of Cmpt mice contained significantly more glycolytic IIB fibers accompanied by a decreased number of IIX and IIA fibers; 
however, this was not the case for SOL muscles. In summary, despite the variances found in muscle cellularity between the 
different myostatin mutant mice, similar glycolytic shifts were observed in Cmpt fast muscles as in muscles from myostatin 
knockout mice. ( J Histochem Cytochem 61:889–900, 2013)
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University of Berlin (Bünger et al. 2001). Analysis of the 
Hungarian inbred subpopulation of the Cmpt line identified 
myostatin as the major gene containing a 12-bp non-frame-
shift deletion in the propeptide region, although the biologi-
cally active part of the molecule was unaffected (Varga 
et al. 1997). Additional modifiers seem to be essentially 
involved in determining the full expressivity of the Cmpt 
phenotype; however these genes have not been identified 
yet (Szabó et al. 1998; Varga et al. 2003, 2005). To date, 
few studies describe the phenotypical or molecular analysis 
of the Cmpt mice (Bünger et al. 2004; Rehfeldt et al. 2005; 
Amthor et al. 2007, 2009), even though this line represents, 
in contrast to myostatin KO, a complex and mainly unknown 
mechanism of myostatin-dependent hypermuscularity.
Various contradictory results exist in the literature 
regarding muscle cellularity in myostatin-deficient mice. 
Thus, in the present study, we aimed to describe the muscle 
phenotype of young male Cmpt mice using morphological 
assessments. By analyzing the fast-type tibialis anterior 
(TA) and extensor digitorum longus (EDL) as well as the 
mixed-type soleus (SOL) muscles, we show here that 
hypermuscularity is characterized by either muscle fiber 
hyperplasia or combined hyperplasia and hypertrophy of 
different grades depending on muscle type, and that a sig-
nificant glycolytic shift occurs in the fiber type composition 
of the fast-type muscles of Cmpt mice.
2. Materials and Methods
2.1 Animals
The genetic background of BEHi (Berlin High inbred) line is 
not well defined because it was derived from an out-bred 
line founded from mice bought from pet shops more than 40 
years ago (Bünger et al. 2001). It was initially selected on 
protein mass (Weniger et al. 1974), then on high body 
weight/low fat content (Valle Zarate et al. 1994) and finally 
on body weight (Bünger et al. 2004). The ‘Compact’ line in 
Berlin was derived from the first mice seen in early genera-
tions of the BEH line showing this phenotype, and were 
separated to form a new line that was selected on a muscular-
ity score by visual inspection (Szabó et al. 1998; Varga et al. 
2003, 2005). Animals of the Berlin Cmpt line were used as 
the founders for the Hungarian Cmpt line, and there was no 
further exchange of genetic material between the laborato-
ries in Berlin and Hungary. The Hungarian subpopulation of 
the Cmpt mice was inbred and kept by Géza Müller until 
2010 in the Institute for Animal Biology, Agricultural 
Animal Center, H-2101 Gödöllő, Hungary, and in EGIS 
Pharmaceuticals, Budapest, Hungary. Since 2010, these 
mice have been kept in the Institute of Biochemistry, Faculty 
of General Medicine, University of Szeged, Hungary.
BALB/c mice, serving as wild-type control for the 
experiments, were purchased from Biological Research 
Centre of Szeged, Hungary.
2.2. Experimental Design
Male, 2.5-month (10–12-week)-old Cmpt (44-50.7 g) and 
BALB/c (24-28g) wild-type mice were used for the experi-
ments (n=5–10). Typical hindlimb muscles (quadriceps 
(Quadr), tibialis anterior (TA), extensor digitorum longus 
(EDL), soleus (SOL) and gastrocnemius (Gastro)) of both 
strains were removed under intraperitoneal anesthesia (3% 
chloral hydrate, 0.15 ml/10 g body weight). Older male 
Cmpt mice (4-, 7-, 12-, 18-, and 23-month-old) were also 
used for comparison of body and muscle weight, as well as 
for some fiber analyses of TA muscles. All muscles were 
weighed and frozen in isopenthane/liquid nitrogen and kept 
at -80C until further use. TA, EDL and SOL muscles from 
the right leg were used for morphological and immunohis-
tochemical analysis while RNA isolation and quantitative 
RT-PCR was carried out on the contralateral TA counter-
parts. Animal experiments were approved by the 
Institutional Animal Care and Use Committee at the 
University of Szeged in accordance with the U.S. National 
Institutes of Health guidelines for animal care.
2.3. Morphological Analysis
For morphological analysis, 10-µm serial cryostat sections 
were taken from the mid-belly region of different muscles 
of both Cmpt and BALB/c mice followed by standard 
hematoxylin-eosin (HE) staining. Using images from all 
microscopic fields, we reconstructed the whole cross-
sectional area (CSA) of each muscle using the Cell B pro-
gram (Olympus DP Soft software, Version 3.2., Soft 
Imaging System GmbH; Münster, Germany) and fiber 
number was determined by counting all fibers in TA, EDL 
and SOL muscles using Digimizer software (MedCalc 
Software, Mariakerke, Belgium).
2.4. Myosin Heavy Chain (MHC) 
Immunohistochemistry
Fiber type analysis was carried out on 10-µm thick serial 
cryosections of TA, EDL and SOL muscles from both Cmpt 
and BALB/c wild-type male mice. Sections were first 
blocked in 5% non-fat milk powder in PBS, then incubated 
with mouse monoclonal primary antibodies BA-D5 (1:25), 
sc-71 (1:25) and BF-F3 (1:5), which are specific for myosin 
heavy chain (MHC) I (slow oxidative) MHCIIA (fast oxida-
tive) and MHCIIB (fast glycolytic), respectively (Deutsche 
Sammlung von Mikroorganismen und Zellkulturen [DSMZ], 
Braunschweig, Germany). After incubation with the peroxi-
dase-conjugated secondary antibody (rabbit anti-mouse; 
Dako, Denmark) immunocomplexes were visualized by 
diaminobenzidine (DAB) staining with or without nickel 
enhancement. IIX fibers were considered as those not stained 
by any of the above antibodies. The size and distribution of 
muscle fibers in SOL were determined by analyzing all 
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(700-800) fibers in each muscle using Cell B and Digimizer 
software; in EDL muscles, about 50% of the fibers (600 to 
1100 fibers in BALB/c and Cmpt mice, respectively) were 
measured. In TA muscles, an analysis of fiber size as well as 
fiber type distribution was done by examining 2-3 represen-
tative microscopic fields (with 10x objective) of both super-
ficial and deep portions of TA muscles. Regional results 
were then summarized for the whole cross-sectional area of 
each TA muscle (500 to 1000 fibers/muscle in 4-7 micro-
scopic fields in BALB/c and Cmpt mice, respectively).
2.5. Quantitative RT-PCR Analysis
Total RNA was isolated from TA muscles of Cmpt and 
BALB/c male mice (n=5) with TRI reagent according to the 
manufacturer’s instructions (Molecular Research Center, 
Inc. Cincinnati, OH), followed by reverse transcription 
(MMLV-Moloney Murine Leukemia Virus Reverse 
Transcriptase, 28025-013, Sigma-Aldrich, St. Louis, MO). 
For the detection of transcript levels of MHCI, MHCIIA, 
MHCIIX and MHCIIB, quantitative PCR was carried out 
with SYBR GREEN master mix (Fermentas, Thermo 
Fischer Scientific, Pittsburgh, PA) on a Light Cycler 1.5 
(Roche Applied Science, Indianapolis, IN). As an internal 
control, Hprt (hypoxanthine guanine phosphorybosyltrans-
ferase) was amplified using the same TA muscle probes. 
Cycle conditions were set as an initial denaturation step for 
10 min at 95C, followed by 45 cycles of 10 sec at 95C for 
template denaturation, 10 sec at 58C for annealing phase 
and 10 sec at 72C for extension. Specificity of the PCR 
products was confirmed by melting curve analysis followed 
by verification of the amplicon length on 1.5% agarose gels 
stained with ethidium bromide. Primer pairs for Hprt, 
MHCI, MHCIIA, MHCIIX and MHCIIB were designed 
against sequences of intron-spanning exons by Primer 3 
Input software (version 0.4.0; http://frodo.wi.mit.edu/
primer3/input.htm) and tested to avoid primer dimers, non-
specific amplification and self-priming (Table 1).
2.6. Statistical Analysis
Statistical analysis was performed by unpaired t test using 
Prism software (GraphPad Software, Inc.; San Diego, CA). 
Age-dependent body and muscle weights of Cmpt mice 
(Fig. S1) were tested using a one-way ANOVA and 
Newman-Keuls multiple comparison tests. All data are 
expressed as the mean ± SEM. The level of p<0.05 was 
considered significant. The individual p-values are indi-
cated in the legends to each figure.
3. Results
3.1. Body and Muscle Weight of Cmpt Mice
We phenotypically compared 2.5-month-old myostatin 
mutant Cmpt mice (Varga et al. 1997) with wild-type 
BALB/c mouse using scores of body and muscle weight. 
Cmpt male mice were significantly larger than BALB/c 
mice in terms of body weight (Fig. 1A). Absolute weights 
Table 1. Primer sequences of different MHC isoforms and Hprt used in qRT-PCR.
Target Accession number Forward primer Reverse primer Product size (bp)
MHCIIB NM_010855.2 GTGATTTCTCCTGTCACCTCTC GGAGGACCGCAAGAACGTGCTGA 280
MHCIIX NM_030679.1 ACGGTCGAAGTTGCATCCC CAGTAGTTCCGCCTTCGGTC 272
MHCIIA NM_001039545.2 TGCACCTTCTCGTTTGCCAG GGCCATGTCCTCGATCTTGT 320
MHCI NM_003689292.1 CTACAGGCCTGGGCTTACCT TCTCCTTCTCAGACTTCCGC 126
Hprt NM_013556.2 TCAGTCAACGGGGGACATAAA GGGGCTGTACTGCTTAACCAG 142
bp: base pair; MHC: myosin heavy chain; Hprt: Hypoxanthine guanine phosphorybosyltransferase.
Figure 1. Body weight (A) and 
normalized muscle mass (B, C) of 
BALB/c and Cmpt male mice. B-C 
show normalized muscle masses of 
quadriceps (Quadr), gastrocnemius 
(Gastro), tibialis anterior (TA), 
extensor digitorum longus (EDL) and 
soleus (SOL) muscles. Bars represent 
mean ± SEM; asterisks show significant 
differences between BALB/c and Cmpt 
mice (n=5-10, *p<0.05, ***p<0.001).
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of the different hindlimb muscles, such as Quadr, Gastro, 
TA, EDL and SOL muscles, were significantly larger in 
Cmpt mice (data not shown). Similarly, muscle weights, 
normalized to body weights, were significantly larger in 
Cmpt animals, with the exception of the oxidative SOL mus-
cle. These results indicated a disproportionate increase in 
mass for most muscles of Cmpt mice (Fig. 1B-C). To assure 
that the 2.5-month-old Cmpt mice had already finished the 
intense growing phase, we compared body and muscle (TA, 
EDL and SOL) weights in mice of different ages (Fig. S1). 
Body weight was similar in young (2.5-month-old) and adult 
(4- and 7-month-old) animals, while 12–23-month-old mice 
had slightly higher weight measurements. However, no sig-
nificant difference was found in muscle weights amongst 
any of the age groups, indicating that the 2.5-month-old ani-
mals we used for the experiments have already reached mus-
cle sizes typical of adult mice.
3.2. Muscle Fiber Number and Fiber Cross-
sectional Area
To define whether the hypermuscularity of Cmpt mice is 
caused by hyperplasia or hypertrophy within the muscle, we 
analyzed muscle fibers on HE- or MHC-immunostained 
serial cross-sections of different muscle types—glycolytic 
TA and EDL muscles and oxidative SOL muscles—in both 
mutant and wild-type groups (Fig. 2). Fiber number in all 
examined muscles of the 2.5-month-old Cmpt mice was sig-
nificantly higher than that observed in wild-type mice. The 
TA muscle demonstrated the most significant hyperplasia 
as compared with the EDL and SOL muscles (Fig. 2A). 
However, fiber size did not differ in TA muscles between 
Cmpt and BALB/c mice. EDL and SOL muscles of Cmpt 
mice, on the other hand, showed evidence of hypertrophy 
(Fig. 2B). To check whether older Cmpt mice also show 
changes in fiber parameters, we analyzed TA muscles of 
7-month-old Cmpt mice and found no differences in mean 
fiber number or size compared with the 2.5-month-old 
Cmpt mice (fiber number: 5450 ± 135 vs. 5455 ± 114; fiber 
size: 2193 ± 95 vs. 2114 ± 118, respectively) (Table S1). In 
summary, based on our results, hypermuscularity of Cmpt 
mice is characterized by fiber hyperplasia in TA muscles 
and by a combination of hyperplasia and different grades of 
hypertrophy in EDL and SOL muscles.
3.3. MHC Composition and Fiber Size 
Distribution
To analyze the possible effects of the Cmpt mutation on 
MHC composition, serial cryosections of TA, EDL and 
SOL muscles were immunostained using sets of monoclo-
nal antibodies in order to differentiate type I, IIA, IIX 
and IIB fibers (Figs. 3-6). In line with the literature 
(Bloemberg et al. 2012), only MHCII isoforms were 
detected in TA and EDL muscles of both mouse lines (Figs. 
3-6). Whereas, no MHCIIB fibers were found in SOL mus-
cles. Therefore, we next analyzed the parameters of the 
slow-type I and the fast-type IIA and IIX fibers in SOL 
muscles (Figs. 3-6).
By counting different fiber types on whole cross- 
sectional images, we noted that the fast-type TA muscles of 
Cmpt mice contained significantly more glycolytic IIB 
fibers and a decreased number of IIX and IIA fibers as com-
pared with that in wild-type mice (Fig. 3, 4, 5A). Fiber com-
position has been shown to be different in superficial and 
deep portions of TA muscles in wild-type mice, with more 
glycolytic IIB fibers at the periphery (Bloemberg et al. 
2012). Therefore, we also compared the regional fiber type 
composition in both mouse lines (Fig. 4, 5B). The number 
of IIB fibers was significantly higher in both superficial and 
deep regions of Cmpt mice compared with that in wild-type 
animals (Fig. 4, 5B). Moreover, in Cmpt mice, both muscle 
regions contained a similar number of IIB fibers, whereas, 
in wild-type BALB/c mice, the IIB fibers were abundant 
only in the superficial region, as expected (Fig. 4, 5B). In 
contrast, the proportion of the glycolytic-oxidative IIX 
fibers significantly decreased in both TA regions of Cmpt 
mice, without any regional difference in fiber number 
Figure 2. Total muscle fiber number 
(A) and average fiber cross-sectional 
area (CSA) (B) of tibialis anterior (TA), 
extensor digitorum longus (EDL) and 
soleus (SOL) muscles in BALB/c and 
Cmpt male mice. Bars represent the 
mean ± SEM; asterisks show significant 
differences between BALB/c and 
Cmpt mice (n=3-5, *p<0.05, **p<0.01, 
***p<0.001).
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(Fig. 4, 5B). In wild-type mice, however, we found a sig-
nificantly higher proportion of IIX fibers in the deep region 
(Fig. 4, 5B). Finally, the number of the oxidative IIA fibers 
was very low, and these were almost exclusively confined 
to the deep region of TA muscles in both mouse strains; 
however, the number of IIA fibers was even reduced in 
Cmpt mutant mice compared with wild-type animals (Fig. 
4, 5B).
Similar to TA muscles, the number of glycolytic IIB 
fibers was higher in the fast-type EDL muscles of Cmpt 
mice, while the number of IIX and IIA fibers was signifi-
cantly lower as compared with that of wild-type mice (Fig. 
3, 5A). In contrast, the oxidative SOL muscles in Cmpt 
mice contained more slow-type I fibers and less fast-type 
IIA fibers than those in wild-type mice, while the number of 
IIX fibers was very low and not different in the two mouse 
lines (Fig. 3, 5A).
Together, our findings clearly demonstrate a substantial 
shift toward a more glycolytic phenotype in the fast-type 
TA and EDL muscles but not in the mixed-type oxidative 
SOL muscles of Cmpt mice.
In line with our results regarding average fiber size (Fig. 
2B), we could not detect any specific hypertrophy for any of 
the IIB, IIX or IIA fiber types in TA muscles (Fig. 5C). 
Indeed, the size distribution of the IIB, IIX and IIA fibers in 
TA muscles revealed only minimal changes in terms of 
peak position or shape of the histograms in Cmpt mice when 
compared with the results seen for wild-type mice (Fig. 
6A). In EDL muscles, however, fiber hypertrophy (Fig. 2B) 
was exclusively caused by the increased size of IIB fibers, 
while the sizes of IIX and IIA fibers were unchanged (Fig. 
5C). In line with these findings, IIB fiber distribution in 
EDL muscles was shifted toward larger fiber size in Cmpt 
mice, while IIX and IIA histograms were not different 
between the Cmpt and BALB/c lines (Fig. 6B). In contrast 
to fast muscles, both I and IIA fibers showed evidence of 
hypertrophy for Cmpt mice (Fig. 5C), such that both fiber 
frequencies shifted toward an increase in size in Cmpt SOL 
muscles as compared with BALB/c SOL muscles (Fig. 6C). 
Because of their low number, IIX fiber size was not ana-
lyzed in SOL muscles.
3.4. mRNA Levels of MHC Isoforms Detected by 
Quantitative RT-PCR
In order to determine the transcript levels of MHC isoforms 
(MHCI, IIA, IIB, IIX), we performed qRT-PCR analysis in 
TA muscles of both Cmpt and BALB/c male mice (Fig. 7). 
Figure 3. Representative immunohistochemical stainings of tibialis anterior (TA), extensor digitorum longus (EDL) and soleus (SOL) 
muscles of BALB/c (A) and Cmpt (B) male mice. Panel A represents whole cross-sectional areas of TA, EDL and SOL muscles stained 
either by MHCIIB antibody (in TA and EDL muscles) or by MHCI antibody (in SOL muscle) in BALB/c mice, and panel B shows the same 
tissue staining for sections from Cmpt male mice. All muscles were stained by diaminobenzidine but Cmpt TA muscle was additionally 
nickel enhanced. Scale bars represent 400 µm for TA, 200 µm for EDL and 200 µm for SOL muscles.
894 Baán et al.
Hprt was used as an internal control because Hprt levels were 
similar in Cmpt vs. wild-type TA muscles (Fig. 7A). We 
found that MHCIIB mRNA levels were significantly 
increased (Fig. 7B), while MHCIIX (Fig. 7C) and MHCIIA 
transcript levels (Fig. 7D) decreased in Cmpt mice compared 
with those values in wild-type mice. The slow MHCI isoform 
was almost undetectable (data not shown). These results are 
in line with those obtained from the immunohistochemical 
analysis, suggesting that the fiber-type shift in the TA muscle 
is regulated at the level of MHC transcription.
4. Discussion
The Cmpt mouse line takes a special place in the group of 
hypermuscular animals carrying naturally occurring myo-
statin mutations, as the propeptide region, not the biologi-
cally active domain, of myostatin is affected. Abnormal 
propeptide structure might play an important role in mis-
folding, inefficient secretion, and/or abnormal processing 
of myostatin in Cmpt mice (Szabó et al. 1998). It has also 
been shown that the Cmpt mutation of myostatin is an 
Figure 4. Immunohistochemical analysis of myosin heavy chain (MHC) isoforms in different regions of tibialis anterior (TA) muscles of 
BALB/c and Cmpt male mice. A-C represent the superficial region of BALB/c mice and D-F depict that of Cmpt mice; G-I and J-L show 
BALB/c and Cmpt deep regions, respectively. HE staining (A, D, G, J) and antibodies against MHCIIA (B, E, H, K) and MHCIIB (C, F, I, L) 
were used. Representative fibers are marked as IIA, IIB and IIX fibers. Scale bars represent 100 µm.
Fiber Typing in Cmpt Mice 895
indispensable yet not satisfactory requirement for the full 
expression of the hypermuscular phenotype, pinpointing 
the significance of additional modifier gene or genes (Varga 
et al. 1997, 2003, 2005).
Since the genetic background of the Cmpt mice is very 
complex and no appropriate genetic control line has been 
available so far, we decided to use BALB/c mice as a 
control for the following reasons: 1) This inbred line was 
used for mapping the myostatin mutation and the modi-
fier genes in Cmpt mice (Szabó et al. 1998); 2) These 
mice are generally used as wild-type controls and their 
muscle parameters as well as fiber composition have 
already been reported (Freitas et al. 2002; Luedecke et al. 
2004); and 3) Muscle characteristics of BALB/c mice are 
similar to those of C57BL/6, another wild-type mice 
used as a genetic background of myostatin KO mice 
(McPherron et al. 1997), suggesting that these lines are 
comparable to some extent (Luedecke et al. 2004; 
Pellegrino et al. 2005; Bloemberg et al. 2012; McKeehen 
et al. 2013).
Figure 5. Fiber type composition (A-B) and mean fiber cross-sectional area (C) in tibialis anterior (TA), extensor digitorum longus 
(EDL) and soleus (SOL) muscles of BALB/c and Cmpt male mice. Panel A represents fiber type composition of all fibers in TA, EDL 
and SOL muscles, while panel B shows regional fiber type distribution of TA muscles subdivided into superficial and deep regions. 
Panel C represents mean fiber cross sectional area (CSA) of the different (I, IIA, IIX and IIB) fibers in TA, EDL and SOL muscles. Data 
are presented as the mean ± SEM. Asterisks show significant differences between BALB/c and Cmpt mice (n=3–4, *p<0.05, **p<0.01, 
***p<0.001) while a crosshatch indicates significant changes between superficial and deep portions of the same TA muscle within a 
specific mouse line (n=3, #p<0.05).
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In the present study we show, in accordance with others 
(Bünger et al. 2004; Rehfeldt et al. 2005; Amthor et al. 
2007, 2009), that body and muscle weights of male Cmpt 
mice are higher than those of wild-type BALB/c mice. 
Body mass is even higher in Cmpt mice (47.7g) than it is 
described for male myostatin KO of the same age (38–41g) 
(McPherron et al. 1997). However, muscle weights nor-
malized to body weight are comparable in both myostatin 
mutant lines, suggesting that Cmpt and myostatin KO mice 
represent a similar grade of muscularity. One exception 
was the SOL muscle, which seemed to be different in this 
regard, as its relative muscle-to-body weight did not 
increase in Cmpt compared with the wild-type mice. 
Indeed, it has been reported earlier that the oxidative SOL 
muscle contained less myostatin transcripts than the glyco-
lytic EDL muscle (Mendler et al. 2000; Wang et al. 2012) 
and that the lack of myostatin had a stronger effect on gly-
colytic muscles than on oxidative ones (McPherron et al. 
1997; Carlson et al. 1999; Hennebry et al. 2009; Wang et al. 
2012). Therefore, we analyzed three different hindlimb 
Figure 6. Frequency distribution of fiber size in tibialis anterior (TA) (A), extensor digitorum longus (EDL) (B) and soleus (SOL) (C) 
muscles of BALB/c and Cmpt male mice specific to each myosin heavy chain (MHC) isoform: MHCIIB, MHCIIX, MHCIIA and MHCI. 
CSA, fiber cross-sectional area.
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muscles: the fast-glycolytic TA and EDL as well as the 
oxidative SOL muscles in Cmpt mice.
Based on extensive morphological analyses, measuring 
and counting all fibers on HE-stained cross sections and 
500–1000 fibers on MHCIIB-stained sections, the TA mus-
cles were exclusively characterized by muscle fiber hyper-
plasia, with an absence of hypertrophy. This observation 
may be somewhat surprising, as earlier reports described 
both hyperplasia and hypertrophy in different myostatin 
KO animals (McPherron and Lee, 1997; Amthor et al. 
2009). However, even in the original myostatin KO mouse 
report (McPherron et al. 1997), the ratio of hyperplasia to 
hypertrophy varied in the different muscles; e.g., the TA 
muscles of myostatin KO mice were dominated by hyper-
plasia, while only 14% fiber hypertrophy was documented. 
It is worth mentioning that the myostatin KO vs. myo-
statin+/+ control mice (McPherron et al. 1997) contained 
similar fiber number in TA muscles (5470 vs. 2936) as 
observed with the Cmpt vs. BALB/c mice in our study (5455 
vs. 3093), which makes the KO and Cmpt experiments 
somewhat comparable. In contrast to TA, the EDL muscles 
of Cmpt mice were characterized by a combination of hyper-
plasia (50%) and hypertrophy (20%), whereas, in the myo-
statin KO, the same type of muscles showed only a moderate 
hyperplasia and a stronger hypertrophy (Amthor et al. 2009). 
Amthor and colleagues (2009) compared EDL muscles of 
KO mice with that of the female ‘Berlin’ Cmpt mice 
(BEHc/c). In line with our findings, they also detected stron-
ger hyperplasia in female BEHc/c EDL muscles (1589) than 
in the KO (1200). Interestingly, the fiber number of both 
BEH+/+ and myostatin+/+ controls were also comparable with 
ours (1083 and 1160 vs. 1232, respectively). However, our 
results are somewhat different from those described for the 
BEHc/c females, for which fiber hypertrophy was very pro-
nounced and still dominated over hyperplasia (Amthor et al. 
2009). We found that the moderate fiber hypertrophy in 
Cmpt EDL was confined to the most glycolytic IIB fibers 
and not to the IIX or IIA fibers. This is again in accordance 
with the earlier reports that showed a stronger effect of myo-
statin on glycolytic muscles (McPherron et al. 1997; Carlson 
et al. 1999; Hennebry et al. 2009; Wang et al. 2012). We 
believe that the long separation of the ‘Berlin’ and Hungarian 
Cmpt lines, gender differences, the use of different controls 
as well as the higher number of fibers analyzed in our exper-
iments (3000/1800 fibers in Cmpt/BALB/c vs. 150/180 
fibers in BEHc/c /BEH+/+ (Amthor et al. 2009) may account 
for these differences.
In the oxidative SOL muscle of Cmpt mice, low-grade 
hyperplasia (15%) and mainly hypertrophy (27%) accounted 
for the moderately higher mass of the mice as compared 
with wild-type mice. Moreover, both the oxidative I and IIA 
fibers showed evidence of hypertrophy compared with the 
wild-type mice. The changes in SOL are quite different 
from those of fast TA and EDL muscles in the Cmpt line 
and it is also difficult to compare them to myostatin KO 
mice where either 32% hyperplasia (Girgenrath et al. 2005) 
or 20% fiber hypertrophy has previously been described 
(Gentry et al. 2011).
It is not known so far, how cellularity in different mus-
cle types is regulated upon myostatin defect. However, 
prenatal hyperplasia seems to be the major effect of devel-
opmental myostatin deficiency in most muscles of mice 
and cattle (McPherron et al. 1997; Grobet et al. 1997; Lee 
and McPherron 1997). Based on the different ratio of 
hyperplasia to hypertrophy in various myostatin-deficient 
muscles, myostatin might have a strong, but muscle type-
dependent, effect on the proliferation of muscle precursor 
cells. Consequently, postnatal fiber hypertrophy might be 
restricted to different grades. Rehfeldt and co-workers 
(2005) introgressed the myostatin mutant Cmpt allele into 
a special high-growth mouse line (DUHi) and detected, 
Figure 7. mRNA levels of myosin heavy chain (MHC) isoforms 
and Hprt in TA muscles of BALB/c and Cmpt male mice. Bars 
in B-D represent mRNA levels of MHCII isoforms normalized 
to Hprt transcripts (A). Data are expressed as the mean ± SEM. 
(n=5, *p<0.05, **p<0.01,).
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similar to our results, muscle hyperplasia in the predomi-
nantly fast rectus femoris and longissimus dorsi muscles, 
without any muscle hypertrophy. These data suggest that, 
at least in fast muscles, hyperplasia is even more pro-
nounced in Cmpt mice than in myostatin KO mice. The 
difference might reside in the allelic variation of the myo-
statin defect and/or in modifier genes influencing Cmpt 
phenotype. To show that the dominance of hyperplasia 
(over hypertrophy) found in 2.5-month-old Cmpt muscles 
is not the result of delay in postnatal fiber growth, we ana-
lyzed TA muscles of 7-month-old Cmpt male mice. We 
found a similar hyperplasia without any substantial fiber 
hypertrophy in these older animals, which refutes that the 
increase of fiber size might reach its peak later in adult-
hood in Cmpt mice.
Although TA and EDL muscles contain predominantly 
type II glycolytic fibers (Bloemberg et al. 2012), we observed 
a significant glycolytic shift within type II fibers in Cmpt 
compared with wild-type mice. This result again is consis-
tent with that of Rehfeldt et al. (2005) who found more gly-
colytic fibers in the rectus femoris muscle of the special 
Cmpt-DUHi line by NADH-tetrazolium reductase staining. 
A substantial glycolytic shift was also described in EDL 
muscles of myostatin KO mice as well as in double-muscled 
cattle using different methods (ATPase and SDH staining 
vs. immunohistochemical analysis), showing that both meta-
bolic and structural protein changes occur with a myostatin 
deficiency (Wegner et al. 2000; Girgenrath et al. 2005; 
Amthor et al. 2007). However, immunohistochemical stain-
ing of MHC isoforms used in our study is more appropriate 
to distinguish between fiber types. By this method, signifi-
cantly more IIB fibers and less IIX or IIA fibers were 
detected in TA muscles of Cmpt mice than in wild-type 
mice. Moreover, we analyzed fiber type distribution in 
superficial and deep portions of TA, as there are regional 
differences in glycolytic fibers distribution in wild-type 
mice (Bloemberg et al. 2012). Interestingly, the regional dif-
ference disappeared in Cmpt mice in contrast to wild-type, 
so that both superficial and deep regions of TA muscles 
were dominated by the glycolytic IIB fibers of a quite uni-
form fiber size. Transcript levels were in agreement with our 
immunohistochemical results: MHCIIB mRNA levels were 
significantly higher, while those of MHCIIX and IIA signifi-
cantly lower in Cmpt TA muscles compared with those 
genes in wild-type muscles. These findings suggest that the 
fiber–type shift in fast muscles detected in our study is sup-
ported at the level of both MHC transcripts and proteins.
Likewise, we measured the same ratio of IIB/IIX/IIA 
fibers in EDL muscles of Cmpt mice using immunohisto-
chemical methods, as performed by Amthor and colleagues 
(2007) for myostatin KO mice. The results shows that, in 
fast skeletal muscles, the Cmpt mutation results in similar 
glycolytic changes as the complete lack of myostatin 
protein in the KO mice. The glycolytic shift was consistent 
with the decrease in mitochondrial content, a reduced 
expression of cytochrome c oxidase, a lower citrate syn-
thase activity and a shortening of contraction as well as 
relaxation time in myostatin KO mice (Amthor et al. 2007; 
Savage and McPherron 2010). Moreover, KOs showed 
impaired tolerance to chronic repetitive contractions 
(Ploquin et al. 2012) and a decrease in specific force gen-
eration, similar to that which was measured in BEHc/c 
female EDL muscles (Amthor et al. 2007). These data sug-
gest that the function of the bigger and more glycolytic 
muscles is impaired upon myostatin defect.
However, the oxidative SOL muscles did not show any 
glycolytic shift in Cmpt mice in our experiments (53% 
slow-oxidative type I fibers, 44% fast-oxidative IIA fibers) 
as compared with that in the BALB/c line (38% type I 
fibers, 60% type IIA fibers). In contrast, these fibers had 
even slower oxidative phenotype than the control fibers. 
The fiber type composition we detected in BALB/c SOL is 
in agreement with the literature (Freitas et al. 2002; 
Luedecke et al. 2004) and represents a fiber ratio typical of 
a wild-type SOL, with less than 40% slow-type I fibers 
(Pellegrino et al. 2005; Bloemberg et al. 2012; McKeehen 
et al. 2013). Therefore, it is unlikely that the BALB/c mouse 
was not an appropriate type of control for our experiments 
in this regard. Based on the literature, the more than 50% 
slow-type I fibers in Cmpt animals is rather unusual for a 
SOL muscle in any type of mice, and is different from ear-
lier reports on myostatin KO mice (Girgenrath et al. 2005; 
Gentry et al. 2011; Wang et al. 2012). This suggests that the 
different mechanisms of myostatin deficiency—with or 
without the influence of modifier genes—may induce dif-
ferential and muscle-specific effects.
In summary, Cmpt mouse, in spite of its complex genetic 
background, shows similarities (at least in fast muscles) to 
myostatin KO mice in terms of muscle cellularity and gly-
colytic muscle phenotype, suggesting that the lack of myo-
statin is responsible for these morphological/functional 
changes. However, based on the more pronounced hyper-
plasia in Cmpt fast muscles as well as the different cellular-
ity and oxidative phenotype of Cmpt SOL, additional 
studies are needed to elucidate the molecular mechanisms 
of myostatin inactivity and the possible role of modifier 
genes in Cmpt mice.
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DOI 10.1186/s12967-014-0365-0RESEARCH Open AccessMyostatin and IGF-I signaling in end-stage human
heart failure: a qRT-PCR study
Júlia Aliz Baán1†, Zoltán V Varga2†, Przemyslaw Leszek3, Mariusz Kuśmierczyk3, Tamás Baranyai2, László Dux1,
Péter Ferdinandy2,4, Thomas Braun5 and Luca Mendler1,6*Abstract
Background: Myostatin (Mstn) is a key regulator of heart metabolism and cardiomyocyte growth interacting tightly
with insulin-like growth factor I (IGF-I) under physiological conditions. The pathological role of Mstn has also been
suggested since Mstn protein was shown to be upregulated in the myocardium of end-stage heart failure. However,
no data are available about the regulation of gene expression of Mstn and IGF-I in different regions of healthy or
pathologic human hearts, although they both might play a crucial role in the pathomechanism of heart failure.
Methods: In the present study, heart samples were collected from left ventricles, septum and right ventricles of
control healthy individuals as well as from failing hearts of dilated (DCM) or ischemic cardiomyopathic (ICM) patients.
A comprehensive qRT-PCR analysis of Mstn and IGF-I signaling was carried out by measuring expression of Mstn, its
receptor Activin receptor IIB (ActRIIB), IGF-I, IGF-I receptor (IGF-IR), and the negative regulator of Mstn miR-208,
respectively. Moreover, we combined the measured transcript levels and created complex parameters characterizing
either Mstn- or IGF-I signaling in the different regions of healthy or failing hearts.
Results: We have found that in healthy control hearts, the ratio of Mstn/IGF-I signaling was significantly higher in the
left ventricle/septum than in the right ventricle. Moreover, Mstn transcript levels were significantly upregulated in all
heart regions of DCM but not ICM patients. However, the ratio of Mstn/IGF-I signaling remained increased in the left
ventricle/septum compared to the right ventricle of DCM patients (similarly to the healthy hearts). In contrast, in ICM
hearts significant transcript changes were detected mainly in IGF-I signaling. In paralell with these results miR-208
showed mild upregulation in the left ventricle of both DCM and ICM hearts.
Conclusions: This is the first demonstration of a spatial asymmetry in the expression pattern of Mstn/IGF-I in healthy
hearts, which is likely to play a role in the different growth regulation of left vs. right ventricle. Moreover, we identified
Mstn as a massively regulated gene in DCM but not in ICM as part of possible compensatory mechanisms in the
failing heart.
Keywords: Heart failure, Myostatin, IGF-I, Activin receptor IIB, IGF-I receptor, qRT-PCR, microRNA-208, miRNABackground
Myostatin (Mstn), the growth inhibitor of skeletal muscle
[1], was shown to be expressed in the heart tissue [2] with
controversial data about its role in myocardial physiology
and pathophysiology. Based on the analysis of constitutive
Mstn knockout mice, numerous studies have demonstrated* Correspondence: mendler.luca@med.u-szeged.hu
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unless otherwise stated.that Mstn inhibits cardiac growth and contractility and
induces fibrosis [3-6]. Nevertheless, by analyzing adult
cardiac-specific Mstn mutants we have revealed recently a
beneficial role of Mstn in maintaining cardiac energy
homeostasis and preventing pathological cardiac hyper-
trophy [7].
Insulin-like growth factor I (IGF-I), on the other hand
was shown to play a pivotal role in cardiovascular physi-
ology and aging [8-10]. In concert with insulin itself, IGF-I
proved to be a positive regulator of cardiac growth and
contractility under both physiological and pathological
conditions [11-17]. Previous in vitro studies described ahis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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proposed that Mstn might be a cardiac chalone of IGF-I
since cardiac growth induced by IGF-I was feed-backed by
the overexpression of the negative growth regulator Mstn
[21]. However, no studies have systematically analyzed the
relevance of their possible reciprocal regulation at the
gene expression level in healthy or failing human hearts.
Previous investigations focused only on Mstn protein
activation that has been shown to be accelerated in hearts
of dilated or ischemic cardiomyopathic patients (DCM or
ICM, respectively) [22]. Moreover, no data exist in the
literature about the expression pattern of Mstn in com-
parison with IGF-I and their receptors in various regions
(i. e. left ventricles (LV) versus right ventricles (RV)) of the
human heart. Given the different functional requirements
LV and RV should cope with, and the markedly different
development of these regions, one could assume that the
gene expression pattern of Mstn and IGF-I signaling
might show remarkable spatial differences under both
physiological and pathological conditions. In the present
qRT-PCR study we report that Mstn/IGF-I signaling
differs in LV versus RV even in healthy hearts and shows
significant differences in DCM versus ICM patients.
Methods
Study design
All procedures followed were in accordance with the
ethical standards of the responsible committee on human
experimentation (institutional and national) and with the
Helsinki Declaration of 1975. Informed consent was
obtained from all patients for being included in the study
according to the protocol approved by the Local Ethics
Committee (IK-NP-0021-24/1426/14). Healthy human
hearts were obtained from organ donor patients (CONT,
n = 5) whose hearts were explanted but due to technical
reasons (CMV infection, extensive damage during harvest
and size donor/recipient mismatch), not used for trans-
plantation. The donors did not present any important
previous medical history or any abnormalities in ECG
and echocardiography (LV dimensions/contractility within
normal ranges); these organ donors had died from head
trauma, cerebral or subarachnoid hemorrhage. Explanted
end-stage failing hearts were obtained from patients with
advanced heart failure of non-ischaemic (DCM) (n = 5) or
ischaemic aethiology (ICM) (n = 5). Before transplantation
the clinical state of all patients was determined according
to the New York Heart Association (NYHA) classifica-
tion; patients of NYHA class III–IV underwent a clinical
assessment that included resting electrocardiogram, echo-
cardiography and hemodynamic measurements.
Preparation of cardiac tissue
Tissue samples of the right and left ventricular free walls
and the inter-ventricular septum were taken at the timeof explantation (avoiding scarred, fibrotic, or adipose tissue,
endocardium, epicardium or coronary vessels). The samples
were rinsed immediately, blotted dry, frozen in liquid
nitrogen and kept at − 80°C until further processing.
qRT-PCR analysis of mRNA transcripts
Total RNA was isolated from the LV and RV as well as
from inter-ventricular septum (S) of the CONT, DCM or
ICM patients with the guanidinium thiocyanate-phenol-
chloroform method [23], followed by reverse transcription
(Sigma MMLV- Moloney Murine Leukemia Virus Reverse
Transcriptase, 28025-013). For the detection of the tran-
script levels of myostatin (Mstn), activin receptor IIB
(ActRIIB), insulin-like growth factor I (IGF-I) and insulin-
like growth factor I receptor (IGF-IR) quantitative PCR was
carried out with SYBR GREEN master mix (Fermentas) on
a Light Cycler 1.5 (Roche Applied Science). Since some of
the genes generally used for internal normalization in qRT-
PCR contain several pseudogenes (e.g. GAPDH, beta-actin)
of which co-amplification may compromise their reliability
as reference genes [24], hipoxanthine-guanine phosphory-
bosyltransferase (HPRT) has been used as a single internal
control gene in our experiments. Indeed, HPRT expression
did not significantly change between different groups or
heart regions (data not shown). Cycle conditions were set
as an initial denaturation step for 10 min at 95°C, followed
by 45 cycles of 10 sec at 95°C for template denaturation, 10
sec for annealing phase at 58°C and 10 sec at 72°C for
extension. Specificity of the PCR products was confirmed
by melting curve analysis followed by the verification of the
amplicon length on 1.5% agarose gels stained by ethidium
bromide. Primer pairs for Mstn, ActRIIB, IGF-I, IGF-IR
and HPRT were designed to intron spanning exons by
Primer 3 Input (version 0.4.0) software and tested to
avoid primer dimers, unspecific amplification and self-
priming formation (Table 1).
qRT-PCR analysis of miRNA transcripts
From the above detailed total RNA isolates, cDNA was
synthetized and quantitative real-time PCR was per-
formed with miRCURY LNA™ Universal RT microRNA
PCR kit (Exiqon, Denmark) on LightCycler®480 (Roche,
Switzerland) according to the manufacturer’s instructions.
Briefly, total RNA was diluted to a final concentration of 5
ng/μL, and mixed with Reaction buffer and Enzyme mix
provided with the kit in a final volume of 10 μL. Reaction
mixture was incubated for 60 min at 42°C, and reverse
transcriptase was heat-inactivated for 5 min at 95°C. Then,
cDNA was diluted to 80x and 4 μL of diluted cDNA were
mixed with 6 μL of the PCR Master mix and PCR primer
mix supplied by the manufacturer. The primers for both
microRNA-208b and microRNA-103a-3p was designed
and prepared by using Exiqon’s LNA™ technology. Poly-
merase was activated for 10 min at 95°C, and microRNA-
Table 2 Clinical, echocardiographic and hemodynamic
characteristics of DCM and ICM patients
CONT DCM ICM
Number of samples 5 5 5
Gender (female/male) 3/2 2/3 4/1
Age (year) 29 ± 9 39 ± 10 57 ± 11*#
NYHA functional class III/IV, n n.a. 0/5 3/2
PAP, mmHg n.a. 31.6 ± 4.7 30.8 ± 5.6
PWP, mmHg n.a. 24 ± 4.3 21 ± 3.5
LVED, mm n.a. 68 ± 4 71 ± 4
LVSD, mm n.a. 63 ± 5 61 ± 8
PW, mm n.a. 9.5 ± 0.5 10 ± 1.5
IVS, mm n.a. 10 ± 0.7 11 ± 1.5
LVEF, % n.a. 16 ± 3 23 ± 3
Medications
ACE-inhibitor - ++ ++
β-Blocker - ++ ++
Diuretics - ++ ++
Digitalis - + +
PDE-inhibitor - ++ ++
Dopamine/Noradrenaline ++ ++ +
Statin - - ++
Aspirin - - ++
Desmopressin ++ - -
Values are given in mean ± SEM; *p < 0.05 compared to control; #p < 0.05
compared to DCM Abbreviations: CONT: healthy control individuals, DCM: dilated
cardiomyopathy, ICM: ischemic cardiomyopathy, NYHA: New York Heart
Association, PAP: mean pulmonary artery pressure, PWP: mean pulmonary wedge
pressure, LVED: left ventricular end-diastolic diameter, LVSD: left ventricular
end-systolic diameter, PW: posterior wall thickness, IVS: interventricular septum
thickness, LVEF: left ventricular ejection fraction, ACE: angiotensin converting
enzyme, PDE: phosphodiesterase, n.a.: not applicable.
Table 1 Primer properties used in qRT-PCR
Target Accession number Forward primer Reverse primer Efficiency Product size (bp)
Mstn NM_005259.2 TTCGTCTGGAAACAGCTCCT CATTTGGGTTTTCCATCCAC 1.783 220
ActRIIB NM_001106.3 TGACTTTGGCTTGGCTGTTC ATGTACTCATCCACGGGTCC 1.834 219
IGF-I XM_005268835.1 ATGCTCTTCAGTTCGTGTGTG GGGTCTTGGGCATGTCGGTG 1.758 219
IGFI-R NM_000875.3 GACAACCAGAACTTGCAGCA GATTCTTCGACGTGGTGGTG 1.714 241
HPRT NM_000194.2 TGCTCGAGATGTGATGAAGG TCCCCTGTTGACTGGTCATT 2.044 192
bp: base pair, Mstn: myostatin, ActRIIB: activin receptor IIB, IGF-I: insulin-like growth factor I, IGFI-R: insulin-like growth factor I receptor, HPRT:
hypoxanthine-guanine phosphorybosyltransferase.
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fied (denaturation: 10 sec at 95°C; annealing/synthesis:
1 min at 60°C). The specificity of amplifications was
assessed by melting curve analysis (42°C to 80°C) and by
agarose gel electrophoresis (1%). At last, crossing point
values (Cp) were calculated. MicroRNA-208b Cp values
were normalized to the corresponding housekeeping
microRNA-103a-3p Cp values. Then, all pairwise ΔCp
value normalization was carried out to control ΔCp
values, and expressed as mean of the three replicated of
2-ΔΔCp values (fold change).
Definition of parameters characterizing Mstn and IGF-I
signaling in the heart
In order to describe the additive effect of Mstn and its
receptor ActRIIB transcript levels we combined these
data and defined a multiplied value of Mstn x ActRIIB as
‘Mstn signaling index’ for each analyzed sample. Similarly,
we created a multiplied value of IGF-I x IGF-IR transcript
levels referred to as ‘IGF-I signaling index’. To show the
ratio of Mstn and IGF-I signaling in the different regions
of healthy or failing hearts we divided the measured tran-
script levels by each other to produce either growth factor
ratio of Mstn/IGF-I or receptor ratio of ActRIIB/IGF-IR.
Finally, we created a complex parameter characterizing
the combined ratio of Mstn/IGF-I signaling by dividing
‘Mstn signaling index’ (Mstn x ActRIIB) by ‘IGF-I signal-
ing index’ (IGF-I x IGF-IR) referred to as ‘Mstn/IGF-I
signaling index’ ((Mstn x ActRIIB)/(IGF-I x IGF-IR)).
Statistical analysis
Statistical analysis was performed by one-way/two-way
ANOVA or non-parametric t-test (Welch test) using
Prism software (GraphPad Software, Inc.; San Diego, CA),
as appropriate. All data were expressed as means ± SEM.
For all analyses, a P value <0.05 was considered statisti-
cally significant. The individual P-values are indicated in
the figure legends.
Results
Study patients
A detailed summary of the pre-transplant data and drug
therapy of study subjects are shown in Table 2. Bothfemale and male patients were included in all groups.
The age of ICM patients differed as expected significantly
from both CONTand DCM, since ICM patients are usually
diagnosed with end-stage heart failure later than DCM pa-
tients. DCM and ICM patients were in either NYHA class
III or IV with no difference in pulmonary artery pressure
(PAP, PWP) left ventricle size parameters (LVED, LVSD,
IVS, PW) or left ventricular ejection fraction (LVEF) among
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treated) patients from the study to avoid possible modifica-
tion of the IGF-I signaling by insulin treatment. All patients
were managed with angiotensin-converting enzyme (ACE)-
inhibitors, beta-blockers and diuretics, however, aspirin
and statins were only used in case of ICM patients. CONT
subjects received iv. treatment composed of very low
catecholamine infusion (noradrenaline: 01.-0.2 μg/kg/min,
dopamine: 1-2 μg/kg/min) whereas adequate fluid balance
was maintained with intravenous fluids including colloids
(e.g. Voluven - hydroxyethyl starch) and Desmopressin.Figure 1 Gene expression levels of Mstn and IGF-I as well as their rec
left ventricles (LV) and right ventricles (RV) of control (CONT)-, DCM-,
ActRIIB- (B), IGF-I- (D), and IGF-IR- (E) transcript levels. Panel C shows ‘Mstn
F represents ‘IGF-I signaling index’ (IGF-I multiplied by IGF-IR mRNA levels). Da
(n = 5, *p < 0.05, **p < 0.01).Mstn and IGF-I signaling in healthy control hearts
So far, no comprehensive study has been carried out to
reveal gene expression of the growth regulators Mstn
and IGF-I and their receptors in different regions of
healthy human hearts. In the present work we detected
no significant difference in Mstn (Figure 1A) and ActRIIB
(Figure 1B) transcript levels nor in Mstn signaling index
(Figure 1C) between septum (S), left ventricle (LV) and
right ventricle (RV), however, Mstn levels showed decreas-
ing tendency in the RV (Figure 1A). In contrast, both
IGF-I mRNAs (Figure 1D) and IGF-I signaling indexeptors ActRIIB and IGF-IR normalized to HPRT in the septum (S),
and ICM hearts, respectively. Bars represent normalized Mstn- (A),
signaling index’ (Mstn multiplied by ActRIIB mRNA levels) while panel
ta are expressed in mean ± SEM, asterisks show significant differences
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panied with a significantly higher IGF-IR levels compared
to those of LV (Figure 1E). As a consequence, the ratio of
Mstn/IGF-I gene expression (Figure 2A) as well as those
of ActRIIB/IGF-I receptors (Figure 2B) and finally the
ratio of Mstn to IGF-I signaling (Figure 2C) all showed
significantly higher values in LV/S as compared to RV.
These data clearly demonstrate that Mstn signaling
dominates over IGF-I in the LV more than in RV of
healthy human hearts.
Mstn and IGF-I signaling in DCM patients compared to
healthy controls
In DCM patients we measured massive upregulation of
Mstn mRNA (Figure 1A) associated with an increased
Mstn signaling index (Figure 1C) in all heart regions
compared to CONT, although ActRIIB levels remained
relatively unchanged (Figure 1B). Similar to healthy hearts,
we found a significant upregulation of IGF-I transcripts
(Figure 1D) as well as of IGF-I signaling index (Figure 1F)
in RV of the failing hearts when compared to those of S,
although IGF-IR expression did not show significant
difference in either region nor in comparison to CONT
hearts (Figure 1E). Thus, the ratio of Mstn/IGF-I mRNAFigure 2 Growth factor ratio of Mstn/IGF-I (A), receptor ratio of ActRI
left ventricles (LV) and right ventricles (RV) of control (CONT)-, DCM-,
and IGF-I signaling referred to as ‘Mstn/IGF-I signaling index’ (‘Mstn signalin
IGF-IR)). Data are expressed in mean ± SEM, asterisks show significant differlevels (Figure 2A) and the Mstn/IGF-I signaling index
(Figure 2C) proved to be significantly higher in the left
versus right side of the DCM hearts and showed much
higher levels than those of the CONT regions. Since the
ratio of the ActRIIB/IGF-I receptors (Figure 2B) did not
change significantly we can conclude that Mstn was upreg-
ulated in all regions of failing hearts in DCM patients as
compared to CONT. However, given the higher IGF-I
levels in RV, left and right side of failing heart differed sig-
nificantly from each other in regard to the ratio of Mstn/
IGF-I signaling similar to those of healthy ones (Figure 2C).
Mstn and IGF-I signaling in ICM patients compared to
healthy controls
In contrast to DCM patients, we could not detect any
difference in either Mstn (Figure 1A) or ActRIIB transcript
levels (Figure 1B) or in Mstn signaling index (Figure 1C)
in any heart region of ICM patients compared to those of
CONT. Similarly, IGF-I (Figure 1D) and IGF-IR levels
(Figure 1E) as well as IGF-I signaling index (Figure 1F) did
not differ in ICM heart regions; however, in comparison
to CONT IGF-I showed a decreasing tendency of expres-
sion in the RV, while increased expression of IGF-IR in
the LV was present. Consequently, both ratios of Mstn/IB/IGF-IR (B) and ‘Mstn/IGF-I signaling index’ (C) in the septum (S),
and ICM hearts, respectively. Panel C represents the ratio of Mstn
g index’ divided by ‘IGF-I signaling index’ (Mstn x ActRIIB)/(IGF-I x
ences (n = 5, *p < 0.05, **p < 0.01, ***p < 0.001).
Figure 3 Summary of gene expression alterations regarding
myostatin (Mstn) and IGF-I signaling in healthy human hearts
as well as in DCM and ICM patients, respectively. Bigger circles
represent higher expression of the signaling molecules in control vs.
DCM or ICM hearts or in left (left ventricle (LV) + septum (S)) vs. right
(right ventricle (RV)) side of the hearts.
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similar in all analyzed regions of ICM hearts. However,
significantly higher Mstn/IGF-I ratios were revealed in RV
due to decreased IGF-I levels as well as significantly lower
ActRIIB/IGF-IR ratios in LV when compared to CONT
hearts (due to increased IGF-IR levels). In summary, ICM
hearts did not show significantly altered modulation of
Mstn signaling in either heart region, whereas IGF-I sig-
naling, in contrast to the healthy situation, seemed to be
moderately induced in the LV, while inhibited in the RV.
Differences in Mstn/IGF-I signaling between DCM and
ICM patients
Based on our results, all regions of DCM hearts showed
significantly higher Mstn levels (Figure 1A) as well as
elevated Mstn signaling index (Figure 1C) than those of
ICM hearts. Moreover, ActRIIB (Figure 1B) also revealed
increased levels in LV of DCM vs. ICM patients. Never-
theless, we found no significant difference in IGF-I
signaling on the left side of failing hearts (Figure 1D-F),
although significantly less IGF-I transcripts were evident
on the right side of ICM hearts in comparison with that
of DCM ones (Figure 1D). As a consequence, all param-
eters describing the ratio of Mstn to IGF-I signaling
(Figure 2A-C) showed significantly increased values in
the LV of DCM versus ICM hearts. Although in the RV
we have revealed similar signaling ratio in both types of
failing hearts (Figure 2A-C) the reason for that was an
upregulation of Mstn signaling in DCM patients while a
downregulation of IGF-I signaling in ICM heart samples.
miR-208 expression in relation to Mstn expression in DCM
and ICM patients compared to healthy controls
In parallel with the massive upregulation of Mstn mRNA
in the left ventricle of DCM patients we measured a mild
upregulation of miR-208b (1.505 fold change) compared
to CONT. A similar but less pronounced upregulation
was seen in ICM hearts (1.405 fold change) when com-
pared to CONT, however, no significant difference was
detected between DCM and ICM patients.
Discussion
In the present comprehensive qRT-PCR study we have
found that Mstn dominated over IGF-I signaling much
more in the LV than in the RV of healthy human hearts,
and that DCM hearts upregulated Mstn expression in
contrast to ICM hearts. This is the first demonstration
that Mstn/IGF-I signaling differs in LV and RV in healthy
hearts and shows significant alterations in end-stage heart
failure due to DCM and ICM (Figure 3).
Several studies exist in the literature, indicating the
presence and/or de-regulation of both Mstn and IGF-I
under different conditions in the heart tissue, however,
the majority of data were collected from whole hearts orseparately from the LV [2,11,12,22]. Regarding Mstn
expression in healthy hearts, only one study has been
published so far on higher transcript levels of Mstn in
LV as compared to RV in young piglet hearts [25]. In line
with these data we have demonstrated here an obvious
reciprocal regulation of Mstn and IGF-I in LV compared
to RV characterized by elevated ratios of both Mstn/IGF-I
and ActRIIB/IGF-IR transcripts in healthy human LV
(Figure 3). Septum (S) samples, as being part of LV from
the functional point of view, revealed similar values to
those of LV in most cases. We assume that cardiomyocyte
growth in LV/S should be balanced more tightly by
growth inhibitors (i.e. Mstn) than that of RV since LV is
exposed to higher-pressure overload, while RV to a rela-
tively higher-volume overload. In addition to Mstn and
IGF-I, several other factors have been reported to be
enriched in either LV or RV; their asymmetric expression
might reflect a molecular predisposition of myocardium
to LV-concentric and RV-eccentric remodeling during
postnatal development [25,26]. Similarly, higher expres-
sion levels in LV vs. RV have been demonstrated for cyto-
chrome c oxidases and PGC1α, both of which are known
to contribute to maintain oxidative metabolism [27]. Re-
cently, we have also shown that Mstn plays an important
role in the regulation of oxidative metabolism of the myo-
cardium [7]. Therefore our results support the idea that
the elevated ratio of Mstn/IGF-I signaling is an important
regulatory mechanism under physiological conditions
maintaining higher workload and oxidative metabolism
in the LV.
In human failing hearts (in whole hearts or LV), Mstn
protein activation was reported to be accelerated in both
DCM and ICM patients [22]. In parallel with this obser-
vation several groups found increased serum levels of
Mstn protein in patients suffering from heart failure,
although no correlation was demonstrated with the
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also consider that elevated serum myostatin levels in
cardiomyopathic patients might be a combined effect of
increased secretion from both cardiac and skeletal muscles,
although exercise training lead to a reduction of myostatin
levels only in skeletal muscles but not in serum of patients
with chronic heart failure [31]. Nevertheless, it has been
not clarified, whether protein activation in failing heart is
regulated either at the level of gene expression or post-
transcriptionally. Here we show that DCM hearts are
indeed characterized by upregulated Mstn transcripts
in both LV/S and RV supporting the previous reports
on protein activation in LV [22]. However, we could not
detect any significant elevation of Mstn transcript levels
in ICM patients (Figure 3). We also tested the miRNA-
dependent posttranscriptional regulation of Mstn. MiR-
208 have been reported to be a negative regulator of Mstn
expression [32], and to be upregulated in various forms of
cardiomyopathy [33,34] and myocardial ischemia [35]. In
line with these we detected a mild upregulation of miR-
208b in the LV of DCM patients characterized by massive
increase of myostatin transcripts that might suggest an
adaptive counter regulatory mechanism fine-tuning the
expression of Mstn during heart failure. Since we have
found no difference in miR-208b expression between
DCM and ICM hearts, it is likely that higher levels of
myostatin mRNAs are mainly regulated at the level of
transcription.
Although alterations in Mstn gene expression are
followed by similar changes at the protein level in most
cases [36-38], the (extracellular) promyostatin-pool might
be posttranslationally activated by the cleavage of the
propeptide [39-41]. Thus, ICM patients might have a
Mstn activation at the protein level [22], however, not at
the level of gene expression, whereas DCM hearts react
with significant upregulation of Mstn transcripts. Similar
to the results of George et al. [22] we detected lower level
of ActRIIB in ICM than in DCM patients, but this
occured only in the LV. On the other hand, IGF-I expres-
sion was shown to be dynamically regulated in the course
of heart failure as an important compensatory mechanism;
however, conflicting data exist in the literature with both
down- and upregulated IGF-I levels in end-stage heart
failure [11,14,15]. We could confirm significant decrease
of IGF-I signaling in the RV of ICM patients but not in LV
or in DCM patients. Moreover, DCM patients still main-
tained the physiological difference in Mstn/IGF-I signaling
ratios in LV vs. RV, whereas no asymmetric gene expres-
sion pattern was detected in ICM patients (Figure 3). The
mechanisms leading to different regulation of growth
factor signaling in DCM and ICM patients remain to be
clarified, however, it might relate to the different pathome-
chanism of heart failure and/or alternative regulation of
compensatory mechanisms. Indeed, Mstn upregulationdetected in DCM hearts might be part of the compensa-
tion reactions since we have reported recently that acute
cardiac-specific deletion of Mstn in adult mouse hearts in-
duces dilated cardiomyopathy followed by a massive com-
pensatory up-regulation of Mstn in non-cardiomyocytes
[7]. It is known, however, that various cardiac disease
conditions, i.e. hypoxia can result in an imbalance of
chamber-associated gene expression in myocardium
[25-27,42]. Therefore, ICM hearts of ischemic origin
might not be able to compensate as effective as do DCM
patients by upregulating Mstn to maintain oxidative
metabolism [7] and by regulating their IGF-I signaling
to counter-act the decreased contractility [11]. However,
further research is needed to elucidate the physiological
and pathological relevance of the complex Mstn/IGF-I
network in human heart.Conclusions
Altogether, our results uncovered a spatial asymmetry in
the expression pattern of Mstn/IGF-I in healthy hearts,
which is likely to play a role in the different growth
regulation of LV vs. RV. Moreover, we identified Mstn as a
massively regulated gene in DCM but not in ICM as part
of possible compensatory mechanisms in the failing heart.Limitations
A clear limitation of the study is that our conclusions are
only based on transcript data. However, our goal was to
clarify transcriptional and posttranscriptional regulation of
myostatin/IGF-1 signaling which is missing from the lit-
erature and not the recapitulation of other studies mainly
concentrating on protein changes in heart failure patients
[22,28-30].
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